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1 Introduction 
 
 
1.1 Importance of drug target identification and validation  
 
Today, two strategies may be in principal pursued for treatment of diseases, namely (i) 
surgical and (ii) pharmacological intervention. The human anatomy as base for a ra-
tional surgical intervention has been known in detail for a very long time. Despite the 
notable scientific progresses in the last decades, the pharmacological-, biochemical- and 
molecular biological processes as base for a rational pharmacotherapy are instead rather 
poorly understood and very complex. Although certain molecular pathways have been 
largely characterised, pharmacotherapy focusses on only about 100 proteins. Since the 
human proteome is estimated to consist of 30,000 - 200,000 different proteins [1-2], 
today’s pharmacotherapy is only limited to a small fraction of possible targets. 
To be efficacious, a drug has to bind a target structure and thereby influence its activity. 
Today, medicinal chemistry focusses mainly on the identification and development of 
new drugs to known targets (i.e., target-oriented drug discovery). Therefore high 
throughput screenings are performed to identify lead compounds for appropriate targets 
and furthermore optimise these lead compounds to obtain drugs with high efficacy and 
selectivity. Although this strategy results in a large number of drugs, it suffers from a 
number of drawbacks: (i) It focusses only on a few known targets, thus only a limited 
number of diseases can be addressed by the drugs obtained by this methodology. (ii) 
Side effects caused by interaction with other targets (off-targets) can not be recognised 
in the early stages of drug development. (iii) Compounds (e.g., natural compounds) that 
are known to have beneficial effects in certain diseases as well as low side effects are 
neglected if they do not interact with a determined target. 
Furthermore, although modern drugs are designed and optimised for one particular tar-
get, they often show side effects that are inexplicable with the interaction to the known 
target. For instance, statins as lipid lowering drugs show also anti-inflammatory proper-
ties [3-4]. 
While drugs that affect multiple targets were seen as so called “dirty drugs” due to their 
complex variety of side effects, scientists today try to develop systematically so called 
“multi-target drugs” for the treatment of complex diseases with multiple pathogenic 
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factors [5-9]. Regardless of whether a drug is designed to affect only one or multiple 
targets, a thorough understanding of all targets is required for a rational use in pharma-
cotherapy. 
 
 
Usually, targets for known compounds are discovered by testing them in functional as-
says for estimated targets. This strategy suffers from the same drawbacks as target-
focussed drug development, and again only a small part of possible targets are covered. 
However, diverse techniques and new approaches offer the opportunity to search sys-
tematically target candidates for drugs and natural compounds, which may be of par-
ticular interest for those drugs which have shown efficacy in certain pathologic condi-
tions. Also, these methods might help to characteris biochemical and molecular biologi-
cal processes by identifying unknown receptors for endogenous mediators (i.e., drugs as 
tools). These methods are: (i) affinity based approaches, like the target-fishing [10-11], 
which allow to identify new targets having a certain affinity to the ligand, and (ii) activ-
ity based approaches, like activity-based protein profiling (ABPP) [12-17], which allow 
to identify targets that are affected in their activity by the ligand. Thus, these methods 
are independent of the state of scientific knowledge and can thereby contribute to the 
discovery of new therapeutic options. 
 
 
1.2 The target-fishing approach 
 
Pull-down assays are suitable and valuable tools to evaluate drug-target interactions as 
well as a vast variety of other ligand-protein interactions. In so-called target-fishing 
experiments a drug covalently bound to an insoluble matrix is incubated with a cell lys-
ate as source of target protein(s). Thus, proteins which are bound to the drug (ligand) 
can be isolated and identified by appropriate protein analytics (Fig. 1). Examples for the 
successful application of this technique are the identification of human histone deacety-
lase as target for trapoxin [18] and identification of the mammalian target of rapamycin 
(mTOR) as the target of the immunosuppressant FK-506 (rapamycin) [19]. Therefore, 
the target-fishing approach allows the identification of new, so far not considered tar-
gets for known pharmacological active compounds. 
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Figure 1: Outline of the target-fishing approach. The fishing construct (A) consists of drug/ligand 
(III) that is bound via a linker (II) to an insoluble particle (I). After incubation with a cell lysate (B), 
proteins are bound to the fishing construct (C). Bound proteins can be released after an elution step 
(E). To distinguish between specific bound proteins (1) and those protein that bind to the linker (2) 
or the matrix (3), the same experiment is performed with a control construct without ligand (F). 
Proteins eluted from this construct (G) are then known to come from unspecific interactions. 
 
For successful target fishing experiments, several parameters have to be chosen thor-
oughly. The choice of the matrix, the linker, the immobilisation and derivatisation reac-
tions of the ligand as well as buffer compositions, type of protein source and elution 
conditions directly influence the results of a fishing experiment. 
 
 
1.2.1 Ligand immobilisation 
 
One prerequisite for successful target-fishing is an appropriate immobilisation of the 
ligand. Therefore, the following critical requirements have to be considered: (i) The 
ligand has to possess a functional group which allows its immobilisation on a certain 
matrix (e.g. -NH2, -OH, -COOH, -SH groups). (ii) This functional group has to be 
unique in the molecule in order to achieve a selective immobilisation on only one de-
fined position. (iii) The ligand must not possess additional functional groups that facili-
tate reactions with other molecules of the ligand. (iv) The functional group used for 
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immobilisation of the ligand must not be essential for its pharmacological activity in 
order to ensure an appropriate ligand-target interaction. Since only few ligands accom-
plish all these requirements, synthetic approaches to insert protection groups, derivatise 
ligands or completely synthesise ligand derivatives are needed. 
 
 
1.2.2 Fishing matrices 
 
Coupling ligands to insoluble particles (matrix) is an essential step for subsequent target 
fishing experiments. Thus, several aspects have to be considered to choose the correct 
matrix for a certain drug or natural compound, as the chemical composition of the ma-
trix itself, the activation form and the ligand capacity. For the matrix composition, aga-
rose (Sepharose®) is the most common substance used as matrix in affinity based meth-
ods and proteomic approaches. Agarose matrices are developed for the immobilisation 
of peptides or proteins via convenient one step reactions. However, they are not suitable 
for more complex immobilisation strategies. In addition, their use is limited by their 
poor chemical resistance. The solvent for immobilisation reactions on agarose matrices 
has to consist of at least 50% (v/v) water. Hence, reactions that require lipophilic 
ligands or reagents that are not soluble in aqueous solutions can not be performed with 
agarose matrices. Alternatives are represented by matrices consisting of polyme-
thacrylic acid (methacrylat), which are characterised by a higher chemical resistance. 
Furthermore, they are available with about 10-fold higher ligand binding capacity. Ta-
ble 1 summarises the chemical properties of commercial available matrices. 
 
Name Matrix Activation 
form 
Ligand 
capacity 
Spacer Bead size 
EAH Sepharose® 
4B [1] 
Agarose -NH2 7 – 12 
µmol/ml [A] 
1,6-
diaminohexane 
90 µm 
(45-165 µm) 
Epoxy-activated 
Sepharose® 6B [1] 
Agarose Epoxy 19 – 40 
µmol/ ml [A] 
1,4-bis (2,3-
epoxypropoxy-) 
butane 
90 µm 
(45-165 µm) 
Toyopearl AF- 
Amino-650M [2] 
Methacrylat -NH2 100 +/- 30 
µmol/ml [B] 
n.n. 40 -90 µm 
Toyopearl AF-
Epoxy-650M [2] 
Methacrylat Epoxy 0.6 – 1.0 
mmol/g 
n.n. 40 -90 µm 
Table 1: Chemical properties of commercial available matrices: [1] Amersham/ GE Healthcare; [2] 
Tosho Bioscience; [A] calculated per ml drained matrix; [B] Calculated per ml wet resin 
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Besides their chemical composition, matrices differ in their activation form. To perform 
an immobilisation reaction on a matrix a functional so-called active group is required, 
on the surface of the matrix. The most common active groups for pull-down assays are 
primary amino and oxirane (=epoxy) groups. Amino-activated matrices are used to im-
mobilise carboxylic acid containing ligands over an amide bond whereas epoxy-
activated matrices are used to immobilise ligands with hydroxylic-, primary amino- or 
thiol groups creating an ether moiety, secondary amine or a thioether bond. 
 
 
1.2.3 Linker molecules 
 
Linker molecules are needed to connect ligands to an appropriate matrix. A linker for 
target-fishing experiments has to comply with conditions like low protein binding and 
optimal length to allow an effective interaction between the ligand and the binding site 
of the target. However, linker molecules could have even more specialised functions. 
Thus, there are linkers allowing a covalent cross linking between the fishing construct 
and the matrix or chemo- or photosensitive parts that allow cleaving the ligand off the 
fishing construct. 
 
 
1.2.3.1 Photoreactive linker systems 
 
Photochemical reactions offer a smart, non-invasive possibility for intervention in bio-
chemical approaches, thus limiting effects of interfering reagents. Known applications 
of photoreactive linker systems are so called photoaffinity approaches where a molecule 
that has been bound to an affinity matrix is captured by a covalent connection after UV 
irradiation [20], or the release of synthesised peptides from a matrix after solid state 
synthesis [21] by cleaving a UV light sensitive linker system. For the target-fishing ap-
proach an insertion of a pre-determined breaking point would allow to elute target pro-
teins by cleaving off the ligand from the matrix by UV light irradiation (Fig. 2). Hence, 
problems regarding unspecific protein-matrix interactions are essentially by-passed and 
appropriate target analytics are facilitated. 
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Figure 2: Application of photoreactive linker systems in the target-fishing approach: The fishing 
construct (A) is incubated with proteins from a cell lysate (B). After incubation, the construct (C) is 
irradiated with UV light. The photoreactive linker system is cleaved and specific bound proteins (1) 
are released (E), while unspecific bound proteins (2, 3) remain on the matrix (D). 
 
One of the most interesting reactions in this context is the Norrish-Type II reaction 
which was first described in 1937 [22]. The mechanism of this reaction is an in-
tramolecular movement of a γ-hydrogen atom in aldehydes or ketones after UV light 
irradiation (Fig. 3). The resulting diradicals are subsequently fragmented into a corre-
sponding enol and alkene.  
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Figure 3: Norrish-type-II-reaction: UV light exposure of a ketone with a γ-hydrogen atom (1) re-
sults in a diradical (2) after an intramolecular movement of a hydrogen atom. The diradical can 
either form the corresponding cyclobutanol (3) or is fragmented into a corresponding enol (4) and 
alkene (5). 
 
Ortho-nitrobenzylic systems offer all requirements for sufficient cleavage via Norrish 
type II reaction. Since o-nitrobenzylic systems possess adequate daylight stability, their 
use is limited by the very long cleavage half times [23]. In 1995, Holmes et al. devel-
oped an UV light cleavable linker system to cleave small peptides of a matrix after solid 
phase synthesis [21] on basis of o-nitrobenzylic systems. Although several improve-
ments to existing linker systems could be achieved they still have disadvantages which 
hindered their use in proteomic approaches. Long cleavage times with up to 24 h [21, 
24] would support enzymatic degradation and protein processing, thus complicate sub-
sequent protein analytics. 
 
 
1.2.4 Cell lysates 
 
For the fishing approach, a source of abundant target structures is required. Cell lysates 
of isolated blood cells as well as of immortalised cell lines are routinely used. Incuba-
tion of immobilised ligands with these lysates allows the binding of potential targets to 
the ligands. After several washing steps, the proteins can be eluted by addition of deter-
gents or chaotropic agents. Since specific (ligand-bound) proteins are eluted together 
with unspecific (matrix- or linker-bound) proteins, highly appropriate separation meth-
ods must be performed. Unspecific protein binding occurs mainly due to binding to the 
matrix or to the linker, thus appropriate controls are needed to discriminate whether a 
certain protein is fished through specific ligand-target interactions.  
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1.2.5 Elution conditions 
 
Elution of proteins is performed by addition of appropriate reagents. The most specific 
way to elute proteins from ligands is the addition of free ligand in an excess to elute 
targets in a competitive way. However, since fishing experiments are usually performed 
in aqueous buffer solutions, ligands have to be water soluble to be suitable for this tech-
nique. Thus, this elution method cannot be used for the most drugs or natural com-
pounds. 
Additional methods are used to elute proteins by changing the ionic strength, such as 
high salt buffers or by changing the conformation of the proteins, such as sodium dode-
cylsulfate (SDS) buffer or urea buffers. Since protein denaturation by SDS is needed to 
perform gel electrophoretic separation by SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) and urea buffers are needed for protein separation by isoelectric focussing 
(IEF), subsequent protein analytics is most efficient when elution reagents are chosen 
according to the subsequently used separation technique. 
 
 
1.2.6 Analysis of target-fishing experiments 
 
For the identification of a selectively fished target, fished proteins have to be separated 
by gel electrophoresis. After separation, differentiation between specific and unspecific 
bound proteins can be accomplished by comparing proteins fished by the ligand con-
taining construct and the control. Selected proteins can be identified further by mass 
spectrometric proteomic approaches to receive a peptide fingerprint. Bioinformatic 
evaluations are used subsequently to identify the fished protein by matching the peptide 
fingerprint with a protein data bank (Fig. 4). 
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1.2.6.1 Electrophoretic separation of fished proteins 
 
Electrophoresis is a technique to separate charged molecules in an electrical field. The 
classical approach to separate proteins by electrophoresis is the SDS-PAGE using a tris-
/glycine-buffered system [25]. Two dimensional (2D) electrophoresis is a technique 
with increased resolution, where proteins are first sorted by their isoelectric point in the 
first dimension and then separated by SDS-PAGE in the second dimension. 
 
2
2
2
2
2
2
1
3
3
3
3
2
2
1
SDS-PAGE     
(Separation/
Differentiation)
MS-Sequencing
(Identification)
Western Blot
(Validation/ Characterisation)
m/z
Target-Fishing
(Isolation)
A B
BA
(I)
(III)
(IV)
(II)
 
Figure 4: Outline of the workflow for the analysis of a target-fishing experiment. First, a fishing 
experiment with a drug (B) and a reference construct (A) is performed. After elution, (I) proteins 
can be separated and it can be differentiated between specific and unspecific bound proteins (II). 
Specific bound proteins can be subsequently identified by mass spectrometric approaches (III). 
Validation and characterisation is performed by Western blot analysis (IV). 
 
Difference gel electrophoresis (DIGE) is a technique that revolutionised 2D-
electrophoresis in the 1990s. A general problem of 2D-electrophoresis is its poor repro-
ducibility. In fact, running the same samples under the same conditions on different gels 
leads to differing spot patterns, making comparison of 2D gels with different samples a 
very challenging task. In 1997, Ünlü et al. described a method using two fluorescence 
dyes for labelling proteins of two different samples prior to 2D electrophoresis [26]. 
The so called Cy3 and Cy5 dyes are N-hydroxysuccinimide (NHS) ester-activated cya-
nine dyes meeting crucial requirements: (i) these dyes react with the same moieties of 
proteins, namely the epsilon amino groups of lysine residues, (ii) they don’t change the 
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charge and thereby the isoelectric point of proteins, (iii) they have similar molecular 
weight, and (iv) they have distinct fluorescence characteristics such as linearity, sensi-
tivity and a wide dynamic range [27-28] (Fig. 5). 
Labelling two different protein samples with these two dyes allows running them on the 
same 2D gel. With this procedure, problems regarding different spot patterns on differ-
ent gels are completely by-passed. Since its invention, DIGE became a prominent stan-
dard procedure for comparison of expression patterns in tissue proteomics, subcellular 
proteomics and for various proteomic profiling approaches [29-32]. 
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Figure 5: Chemical structures of the CyDye fluors. 
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1.2.7 Target validation and characterisation 
 
After the identification of a putative target, one has to consider that there are direct as 
well as indirect bound targets. Direct specific binding means that the targets interact 
directly with the ligand as shown in Fig. 6. In contrast, an indirect binding means that 
the target could be bound to an adapter protein that is directly bound to the ligand. To 
elucidate whether a target is directly or indirectly bound to a ligand, fishing experiments 
using the isolated protein instead of cell lysates can be performed. Only direct interact-
ing targets can be isolated under such conditions since potential adapter proteins are not 
present in these experiments. 
 
A B C
I II
III
 
Figure 6: Outline of binding events after a target-fishing experiment. A identified putative target (I) 
can either bind directly (A) or via one ore more adapter proteins (II, III) (B) to the immobilised 
ligand. To determine which of both binding events takes place, a fishing experiment with the iso-
lated target protein is performed. Thus, only direct binding events can take place under these ex-
perimental settings. 
 
The target-fishing approach is a tool to identify new target proteins. However, whether 
or not this target is affected in its functionality by the ligand can not be elucidated by 
target-fishing. Therefore, additional experiments, methods and assays are needed to 
evaluate and validate functional effects of the discovered ligand-target interaction. 
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1.2.8 Importance of the target-fishing approach 
 
Although a fishing approach represents a valid technique for target identification and 
can potentially give novel insights into the pharmacological properties of a certain drug, 
it is used rather seldom. On the one hand, this is due to the fact that the properties of the 
fished protein to be analysed are not known in advance and this makes the (blind) opti-
misation of analytical methods a challenging task. On the other hand, an interdiscipli-
nary scientific network consisting of biochemists, synthetic chemists and proteomic 
specialists is needed. This has slowed-down the development of reliable target-fishing 
approaches, and thus suitable methodologies for fishing have been seldom established. 
In this thesis the target-fishing approach has been optimised to identify new targets of 
synthetic and natural compounds which possess anti-inflammatory effects that are not 
readily explicable on the basis of known targets. 
 
 
1.3 Inflammation 
 
Inflammation is a physiological, non-specific immune response characterised by five 
cardinal signs: redness, heat, swelling, pain and loss of function. The aim of the physio-
logical inflammatory response is to limit and delete injurious stimuli and to restore tis-
sue function. Therefore, acute inflammation does not represent a disease; instead it is a 
self limiting physiological process in response to an injurious stimulus. However, the 
persistence of inflammatory stimuli or faulty regulation of the inflammatory response 
may lead to chronic and pathologic conditions. Furthermore, chronic inflammation af-
fects and sustains tumour development and progression [33-35]. Thus, pharmacological 
anti-inflammatory approaches are not only intended as treatment for acute conditions, 
but are rather an essential part of the therapies of a wide range of diseases, such as 
chronic inflammation, pain, bacterial infections, autoimmune diseases and cancer. 
On the cellular level, inflammation is a complex process involving several biochemical 
events and is initiated by the release of pro-inflammatory mediators such as cytokines 
(e.g. interleukin-1, tumour necrosis factor-α), plasma proteins (e.g. bradykinin and 
thrombin), lipid mediators (leukotrienes, prostaglandins) and histamine in response to 
an inflammatory stimulus. As a consequence of the action of the inflammatory media-
tors, the postcapillary venule permeability is increased, permitting leukocyte migration 
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into tissues. In addition, tissue-infiltrated leukocytes release additional pro-
inflammatory agents. Among these, mediators derived from arachidonic acid (all-cis 
5,8,11,14-eicosatetraenoic acid, AA), the so-called eicosanoids, play a key role in the 
regulation of inflammatory processes and are therefore considered a valuable target for 
pharmacological intervention. AA is part of phospholipid membranes. After appropriate 
stimulation, AA is enzymatically liberated by phospholipases A2. Free AA itself can act 
as mediator but is also a substrate for subsequent enzymatic reactions. AA can be trans-
formed by (i) cyclooxygenases (COXs) to prostaglandins and thromboxanes, (ii) by 
lipoxygenases (LOs) (predominantly 5-LO) to leukotrienes or (iii) by different cyto-
chrome P450 enzymes to epoxyeicosatrienoic acids [36]. 
 
 
1.4 Synthetic and natural anti-inflammatory drugs as candidate ligands for the 
fishing approach 
 
1.4.1 Acetaminophen (Paracetamol) 
 
Acetaminophen (ACAP) (Fig. 7) is one of the most used analgesic drugs worldwide. 
Nevertheless its exact mode of action remains unclear and is still under discussion. 
ACAP was first synthesised in 1878 by Morse [37] and has been used as antipyretic 
drug since 1887 [38]. Its broad distribution started in the 1950s after the abandons of 
phenacetin. Today there is still a large interest on ACAP. The amount of publications 
concerning ACAP increased 60-fold in the last 40 years whereas medical publications 
in general only increased threefold in the same time. Interestingly about 70% of the lit-
erature focusses on side effects and clinical use and only 5% consider pharmacodynam-
ics [39]. This leads to a big discrepancy between the wide spread use of this drug and 
the knowledge about its pharmacologic action. 
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Figure 7: Chemical structure of ACAP 
 
Although ACAP is not considered as a classical non-steroidal anti-inflammatory drug 
(NSAID) it possesses beneficial effects in certain inflammatory diseases [40-41]. To-
day, several targets have been discussed to be affected by ACAP. Several effects on the 
eicosanoid pathway, prominently COX-1 and COX-2 inhibition, have been described 
[42-46]. However, neither an inhibition of the COX function nor an inhibition of the 
peroxidase function [47] of COX-1 or COX-2 could explain all pharmacological effects 
of ACAP. Also the opioidergic system as well as the serotonergic- and the cannabinoid 
system were discussed to be affected by ACAP [45-46]. In addition there are studies 
suggesting that ACAP is only a prodrug of the active form AM404 (N-arachodinyl-
phenolamine). The fact that AM404 is found in the central nerve system (CNS) but not 
in blood after ACAP administration could at least explain the central effects of ACAP 
[48-50]. 
In 2002, a new perspective of ACAP was proposed regarding COX as targets. 
Chandrasekharan et al. described that there is a COX-3 that could be selectively inhib-
ited by ACAP [51]. Scientists recognised that this work contains experimental inade-
quacies as well as a lack of general scientific standards [44, 52]. Chandrasekharan et al. 
claimed that in canine COX-3 there is an intron that is not present in the COX-1 mRNA 
having 75% sequence homology with the corresponding intron in human. In fact, this 
intron exists in the human genome but its retention leads to a frame shift and a nonfunc-
tional protein with 8.7 kDa and not to a functional, additional COX. For the specific 
inhibition of COX, it was obtained an IC50 value of 460 µM for COX-3 and over 1000 
µM for COX-1 and COX-2. Since it has been known that the sensitivity of COXs 
against inhibitors depends on their activity [53] and the COX-3 showed only 20% of the 
activity of COX-1 and only 4% activity in comparison with COX-2, the stronger inhibi-
tion of COX-3 by ACAP is explained by its poor activity, and not by a “selective” sen-
sitivity to ACAP. 
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In conclusion neither effects on the opioidergic-, the serotonergic- or the cannabinoid 
system nor inhibition of COXs can explain the anti-inflammatory effects of ACAP. 
Thus, the mechanism of action for one of the most used drugs worldwide remains un-
clear up to date. 
 
 
1.4.2 Resveratrol 
 
Resveratrol (RV, 3,5,4´-trihydroxystilbene) (Fig. 8) is a polyphenolic phytoalexin first 
isolated from Polygonum cuspidatum by Nonomura et al. in 1963 [54]. However, it was 
widely unnoticed until Siemann et al. reported its presence in red wine in 1992 [55]. 
Speculations that this could explain the “French paradox”I [56] brought RV back into 
the focus of interest [57]. 
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Figure 8: Chemical structure of resveratrol 
 
So far RV has been known to influence a wide range of cellular effects. As a polyphe-
nolic compound, RV shows redox activity and antioxidative capacities [58-60]. RV is 
known to reduce carcinogenesis at different levels (e.g. cancer initiation, -promotion, 
and -progression) [59-65] as well as inflammatory diseases [66-67]. Several targets for 
the anti-cancer effects of RV have been determined, such as inhibition of the DNA po-
lymerase [65], inhibition of the ribonucleotide reductase activity [64-65], activation of 
the DNA checkpoint pathways including ataxia telangiectasia mutated/ ataxia telangiec-
tasia-Rad3-related (ATM/ATR) kinase and checkpoint kinase 1(Chk1) [63] as well as 
angiotensin II and epidermal growth factor (EGF) mediated Ak-transformed (Akt) 
kinase activation [68-69]. Anti-inflammatory activities of RV are shown to be due to 
inhibition of both the COX and LO pathway as well as microsomal prostaglandin E2 
synthase 1 (mPGES1) expression [70]. Furthermore RV was found to slow the progres-
                                                 
I
 The “French paradox“ describes the observation that the French people have a relative low incidence of 
coronary heart disease, although they have a diet relatively rich in cholesterol and saturated fat. 
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sion of Alzheimer disease [71], to mimic caloric restriction and to extend the lifespan of 
mice [72]. However the versatile anti-inflammatory properties of RV [66-67, 73-76] can 
only be partially explained by the known targets. 
 
 
1.4.3 Indirubin-3´-monoxime 
 
Indirubine-3´-monoxime (IR3MO) is a 3,2´-bisindole from Indigo naturalis. In tradi-
tional Chinese medicine Danggui Longhui Wan, a recipe consisting of 11 ingredients is 
known to relieve symptoms of chronic myelomic leukaemia [77-78]. In 1966, scientists 
identified Qing Dai, known as Indigo naturalis as the active compound of this recipe. 
Besides high levels of the blue dye indigo, Indigo naturalis contains also an indigo iso-
mer called indirubine (Fig. 9). 
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Figure 9: Chemical structure of indirubin-3´-monoxime (A) and indirubine (B) 
 
In 1999, Hoessel et al. showed that the antileukaemic activity is related to the inhibition 
of several cyclin-dependend kinases (CDKs) [79]. CDKs play a critical role in cell cycle 
regulation. CDKs are activated by binding to cyclins and building holoenzymes. In-
dirubin inhibits CDK activity in the micromolar range. 
Since indirubin shows poor solubility and absorbance but gastrointestinal toxicity, me-
dicinal chemists attempted to synthesise optimised derivatives of indirubin [80-81]. 
Among others, IR3MO was synthesised. Besides better solubility and absorption, 
IR3MO showed a 5- to 50-fold improved inhibitory activity to various CDKs. Besides 
its antitumoural activity, IR3MO also possesses anti-inflammatory properties [82-83]. 
However, a molecular or biochemical basis for the observed anti-inflammatory effects 
does not exist. 
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1.4.4 Myrtucommulone A 
 
Myrtucommulone A (MC) (Fig. 10) is a nonprenylated acylphloroglucinol contained in 
leaves of Myrtus communis. In folk medicine Myrtus communis is known for its antisep-
tic and anti-inflammatory properties. Extracts have been reported to be antibacterial, 
antihyperglycemic and analgesic [84]. 
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Figure 10: Chemical structure of myrtucommulone A 
 
The anti-inflammatory activity of MC is related to interference with several molecular 
targets and the activity of mPGES1 [85], COX-1, 5-LO as well as human leukocyte 
elastase (HLE) release were shown to be influenced by MC [86]. While anti-
inflammatory aspects of MC have been known for a long time and are basically under-
stood, the antiapoptotic action was first reported in 2008 [87]. MC was shown to induce 
cell death with an EC50 values in the low micromolar range. Several characteristics of 
apoptosis such as caspase-3, -8 and -9 activation as well as Poly (ADP-ribose) poly-
merase (PARP) cleavage could be shown selectively for cancer cell lines [87]. Never-
theless, direct molecular targets of MC related to apoptosis induction are still not 
known. 
 
 
1.4.5 Betulinic Acid 
 
Betulinic acid (BA) (Fig. 11) is a plant-derived pentacyclic triterpene. BA is the C-28 
oxidised form of betulin (3β-lup-20(29)-en-3, 28-diol). Betulin was first isolated in 
1788 and was therefore one of the first isolated natural compounds at all. Although 
betulin is present in a vast variety of plants it is named after the white birch tree (Betula 
alba) whose bark consists up to 30% (dry weight) betulin [88]. BA itself is also present 
in a large number of plants [89-90]. Since the BA content in plants is rather low, it is 
obtained by oxidising betulin isolated from Betula alba [89]. The bark of Betula alba 
was traditionally used by native Americans for the treatment of several diseases [90]. In 
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1994, Fujioka et al. stated that BA is able to inhibit the replication of the human immu-
nodeficiency virus (HIV) [91]. As result of this work, the BA analogue bevirimat is 
under further investigation in a phase II clinical trial for the treatment of HIV-1 infec-
tions [92-93]. 
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Figure 11: Chemical structure of betulinic acid (A) and betulin (B) 
 
Beside its antiviral activity, BA also possesses antitumoural effects first described in 
1995 [94]. Although there are conflicting results concerning the exact mode of action of 
BA, several components of the intrinsic apoptotic pathway could be identified to be 
affected by BA [89-90]. While the mechanisms of action in inhibition of HIV replica-
tion and antitumoural effects are quite well understood, the described anti-inflammatory 
effects [95] are by today inexplicable. 
 
 
1.5 Gender bias in inflammation 
 
Traditionally, anti-inflammatory pharmacotherapies do not discriminate between men 
and women. However, it has been recognised in the last decades that several inflamma-
tory diseases show a higher prevalence for one of the two genders [96-102] (Tab. 2). 
Also, enormous changes in regard to prevalence and gravity of certain inflammatory 
diseases are observed at puberty, during pregnancy or during the climacteric period 
[103-104], suggesting that sex hormones may play a key role in the regulation of in-
flammation and immune reactions, though also other factors may be involved (genetic-, 
anatomical-, physiological- [105-106], psychological- [107-108] and sociocultural fac-
tors [109-110]). Hence, a comprehensive understanding of gender differences on a mo-
lecular level is needed to facilitate gender specific pharmacotherapy. 
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Disease Ratio fe-
male:male 
reference 
Rheumatoid arthritis 2:1 to 3:1 Alamanos 2005 
Systemic lupus erythematodes 9:1 D´Cruz 2007 
Scleroderma 4:1 Whitcare 2001 
Myasthenia gravis 3:1 Whitcare 2001 
Multiple sclerosis 3:2 Whitcare 2001 
Systemic sclerosis 3:1 Chifflot 2008 
Table 2: Prevalence of inflammatory diseases in male and female subjects. 
 
 
1.6 The steroid hormones testosterone and progesterone as ligands for target-
fishing experiments 
 
Testosterone and progesterone are sex hormones primarily involved in the regulation of 
sexual maturation and reproduction. Testosterone is primarily produced in the gonads 
while progesterone is produced in the ovaries. For their classical mode of action, the 
signalling of both hormones is mediated by corresponding steroid hormone receptors. 
These receptors act as ligand inducible transcriptional enhancing factors. Thus, binding 
of a steroid hormone to a corresponding cytosolic receptor causes dimerisation of the 
receptor, translocation to the nucleus and binding to hormone responsive elements 
(HREs) of the DNA [111-115]. For the progesterone receptor (PR) and the androgen 
receptor (AR) two isoforms are known, respectively. For the PR, PR-A and PR-B are 
known isoforms differing in their promoter usage [116]. The two AR isoforms hAR-A 
and hAR-B are structural analogues to the two PR isoforms [117]. However, the exact 
contribution and functional differences of PR and AR isoforms are not known. 
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Figure 12: Chemical structure of testosterone and progesterone 
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Although the genomic effects mediated by AR and PR have been extensively investi-
gated and are understood in terms of triggering mechanisms, there are hormonal effects 
that can not be explained by the classical genomic regulation. In fact, testosterone and 
progesterone are known to induce very rapid effects (seconds to minutes), also in cells 
devoid of the classical hormone receptor, which are clearly not compatible with a ge-
nomic regulation. These recent evidences indicate the existence of additional targets for 
testosterone and progesterone that are responsible for these so-called non-genomic ef-
fects. Examples of non-genomic hormonal effects are: (i) a rapid change of intracellular 
Ca2+ after androgen exposure in Sertoli-, LNCap- and T-cells [118-121]. (ii) Changes in 
membrane fluidity in mammary cancer cells [122-123] resulting in an increased 
Na+/K+-ATPase and Ca2+-ATPase activity [124-126]. (iii) Activation of second mes-
senger pathways such as cellular-sarcoma (c-Src) mediated mitogen-activated protein 
kinases (MAPK) activation in prostate cancer cells [127-128] or sex hormone binding 
globulin (SHBG) receptor mediated activation protein kinase A (PKA) in breast cancer 
cells [129-130]. (iv) Rapid regulation of gonadotropin-releasing hormone (GnRH) re-
lease in neuronal cells [131-135]. (v) Extracellular-signal-regulated kinase (ERK) medi-
ated regulation of 5-LO activity in neutrophils [96]. 
Although some targets have been suggested to explain at least some of these effects, 
clear evidences for the existence of additional receptors responsible for the non-
genomic actions of these sex-hormones are still missing. 
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2 Aim of the study 
 
Today, two strategies may be in principal pursued for treatment of diseases, namely (i) 
surgical and (ii) pharmacological intervention. The human anatomy as base for a ra-
tional surgical intervention has been known in detail for a very long time. Despite the 
notable scientific progresses in the last decades, the pharmacological-, biochemical- and 
molecular biological processes as base for a rational pharmacotherapy are instead rather 
poorly understood and very complex. Although certain molecular pathways have been 
largely characterised, pharmacotherapy focusses on only about 100 proteins. Since the 
human proteome is estimated to consists of 30,000 - 200,000 different proteins [1-2], 
today’s pharmacotherapy is only limited to a small fraction of possible targets. 
 
For a rational pharmacotherapy, a comprehensive understanding of the molecular phar-
macological interactions of drugs with the respective targets is necessary. However, the 
mechanism of action of many drugs commonly used in therapy is so far only partially 
understood. The overall molecular actions of many drugs and natural compounds often 
appears like a patchwork obtained by testing these compounds in a limited number of 
well established systems. Thus, there is a lack of knowledge caused by a lack of meth-
ods that allow a systematic and reliable discovery of drug targets. 
The aim of this work was to refine and improve the target-fishing approach in order to 
receive a reliable, standardised and convincing tool for the identification of new targets 
for natural compounds and synthetic agents used as drugs. The following methodologi-
cal issues were approached: (i) evaluation of various matrix types, (ii) development of 
new immobilisation strategies, (iii) systematic evaluation of fishing and elution condi-
tions, (iv) development of photoreactive linker systems, (v) establishment of the 2D-
DIGE approach and its optimization in relation to the particular requirements of target-
fishing eluates. Furthermore, this work aimed also to confirm the success of these tech-
nical improvements by performing fishing-experiments using selected baits with phar-
macological potential (i.e. acetaminophen, resveratrol, indirubin-3´-monoxime, myrtu-
commulone A, betulinic acid, progesterone and testosterone) and by the subsequent 
evaluation and validation of the ligand-target interactions. 
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3 Materials and Methods 
 
3.1 Materials 
3.1.1 Chemicals 
 
Name Supplier 
1-(3-Dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride 
Acros Organics (Geel, Belgium) 
1,6-Diisocyanatohexane Acros Organics (Geel, Belgium) 
2-[4-(2-Hydroxyethyl)-1-
piperazine]ethanesulfonic acid 
AppliChem GmbH (Darmstadt, Germany) 
2-Cyclopentenone Acros Organics (Geel, Belgium) 
4-Aminophenol Acros Organics (Geel, Belgium) 
5,5´-Dithio-bis(2-nitrobenzoic acid) AppliChem GmbH (Darmstadt, Germany) 
5-Bromo-4-chloro-3-indolyl phosphate, 
p-toluidine salt 
AppliChem GmbH (Darmstadt, Germany) 
5α-Dihydrotestosterone Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Acrylamide solution 30% (37.5:1) AppliChem GmbH (Darmstadt, Germany) 
AG® 501-X8 Resin Bio-Rad Laboratories, Inc. (Hercules, 
CA, USA) 
Agar-Agar Merck KGaA (Darmstadt, Germany) 
Ammonium persulfate AppliChem GmbH (Darmstadt, Germany) 
Ampholyte Bio-Lyte3/10® Bio-Rad Laboratories, Inc. (Hercules, 
CA, USA) 
beta-Mercaptoethanol Carl Roth GmbH + Co. KG (Karlsruhe, 
Germany) 
Betulinic acid Alexis Corporation (Lausen, Switzerland) 
BioRad DC Protein Assay Kit Bio-Rad Laboratories, Inc. (Hercules, 
CA, USA) 
Boc-Ala-Ala-Nva-SBzl (PR3 substrat) EPC 
Bromophenol Blue Merck KGaA (Darmstadt, Germany) 
Calciumchloride AppliChem GmbH (Darmstadt, Germany) 
Chaps AppliChem GmbH (Darmstadt, Germany) 
Chemoluminescence films (Amersham 
HyperfilmTM ECL 
GE Healthcare GmbH (Freiburg, 
Germany) 
Cy 2,3,5 5nmol CyDye DIGE Fluor 
minimal Dye labelling Kit 
GE Healthcare GmbH (Freiburg, 
Germany) 
Cy3 Bis NHS ester GE Healthcare GmbH (Freiburg, 
Germany) 
Cy5 Bis NHS ester GE Healthcare GmbH (Freiburg, 
Germany) 
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Name Supplier 
Cytochalasin B AppliChem GmbH (Darmstadt, Germany) 
Dextran Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Dimethylformamide 99.8% extra dry Acros Organics (Geel, Belgium) 
Dioxane Carl Roth GmbH + Co. KG (Karlsruhe, 
Germany) 
Disodium hydrogen phosphate dihydrate Merck KGaA (Darmstadt, Germany) 
Dithiothreitol AppliChem GmbH (Darmstadt, Germany) 
Dulbecco’s modified Eagle's medium 
(DMEM) 
PAA Laboratories GmbH (Pasching, 
Austria) 
Dulbecco’s buffer substance Serva Electrophoresis GmbH 
(Heidelberg, Germany) 
Epoxy-activated Sepharose® 6B GE Healthcare GmbH (Freiburg, 
Germany) 
Escin Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Ethylenediaminetetraacetic acid AppliChem GmbH (Darmstadt, Germany) 
Eupergit C250L Degussa / evonik industries (Darmstadt, 
Germany) 
Fatty acid free BSA Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Fetal calf serum (FCS) Sigma-Aldrich Inc. (St. Luis, MO, USA) 
FK-866 Biozol Diagnostica Vertrieb GmbH 
(Eching, Germany) 
Flamingo Fluorescent Gel Stain 10x Bio-Rad Laboratories, Inc. (Hercules, 
CA, USA) 
Formaldehyde Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Galacturonic acid Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Glycerol Caesar & Lorentz GmbH, (Hilden, 
Germany) 
(L)-Glycine AppliChem GmbH (Darmstadt, Germany) 
Hepes solution (for cell culture) PAA Laboratories GmbH (Pasching, 
Austria) 
Horse serum PAA Laboratories GmbH (Pasching, 
Austria) 
HybondTM-C Extra nitrocellulose  mem-
branes  
GE Healthcare GmbH (Freiburg, 
Germany) 
Indole-3-carbinol Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Iodoacetamide Sigma-Aldrich Inc. (St. Luis, MO, USA) 
IPG Strips (ReadyStrip™) 17 cm 3-10NL Bio-Rad Laboratories, Inc. (Hercules, 
CA, USA) 
Leupeptin hemisulfate salt Sigma-Aldrich Inc. (St. Luis, MO, USA) 
(L)-Glutamine solution (for cell culture) PAA Laboratories GmbH (Pasching, 
Austria) 
(L)-Lysin Acros Organics (Geel, Belgium) 
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Name Supplier 
Lupeol Alexis Corporation (Lausen, Switzerland) 
Lymphocyte Separation medium 
LSM 1077 
PAA Laboratories GmbH (Pasching, 
Austria) 
Magnesium chloride Merck KGaA (Darmstadt, Germany) 
Milk powder (blotting degree) Carl Roth GmbH + Co. KG (Karlsruhe, 
Germany) 
Mineral Oil Bio-Rad Laboratories, Inc. (Hercules, 
CA, USA) 
N,N-Dicyclohexylcarbodiimide AppliChem GmbH (Darmstadt, Germany) 
N,N'-Diisopropylcarbodiimide Acros Organics (Geel, Belgium) 
N-[Tris(hydroxymethyl)methyl]glycine AppliChem GmbH (Darmstadt, Germany) 
Sodium chloride Merck KGaA (Darmstadt, Germany) 
Nitro blue tetrazolium (NBT) Roche Applied science (Mannheim, Ger-
many) 
Nonidet® P40 AppliChem GmbH (Darmstadt, Germany) 
Penicillin / Streptomycin solution (for cell 
culture) 
PAA Laboratories GmbH (Pasching, 
Austria) 
peqGOLD IV Protein Molecular weight 
Marker 
PEQLAB Biotchenology (Erlangen, 
Germany) 
Phenylmethylsulphonyl fluoride AppliChem GmbH (Darmstadt, Germany) 
Ponceau S red Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Propylamine Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Protease Inhibitor Cocktail P8340 Sigma-Aldrich Inc. (St. Luis, MO, USA) 
RPMI (Roswell Park Memorial Institute) 
medium  
PAA Laboratories GmbH (Pasching, 
Austria) 
Sclerotiorin Biozol Diagnostica GmbH (Eching, Ger-
many) 
Silver nitrate Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Sodium azide Merck KGaA (Darmstadt, Germany) 
Sodium bicarbonate Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Sodium carbonate Merck KGaA (Darmstadt, Germany) 
Sodium dihydrogen phosphate, anhydrous Merck KGaA (Darmstadt, Germany) 
Sodium dodecyl sulfate AppliChem GmbH (Darmstadt, Germany) 
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Name Supplier 
Sodium nitrite Merck KGaA (Darmstadt, Germany) 
Sodium pyruvate solution (for cell culture) PAA Laboratories GmbH (Pasching, 
Austria) 
Soybean trypsin inhibitor (STI) Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Tetramethylethylenediamine (TEMED) Carl Roth GmbH + Co. KG (Karlsruhe, 
Germany) 
Testosterone Sigma-Aldrich Inc. (St. Luis, MO, USA) 
Tetrahydrofuran (THF) Carl Roth GmbH + Co. KG (Karlsruhe, 
Germany) 
Thiourea AppliChem GmbH (Darmstadt, Germany) 
Toyopearl AF-Amoni 650M Tosho Bioscience GmbH (Stuttgart, Ger-
many) 
Toyopearl AF-Carboxy 650M Tosho Bioscience GmbH (Stuttgart, Ger-
many) 
Toyopearl AF-Epoxy 650M Tosho Bioscience GmbH (Stuttgart, Ger-
many) 
Trichloroacetic acid Merck KGaA (Darmstadt, Germany) 
Triethanolamine Merck KGaA (Darmstadt, Germany) 
Tris(hydroxymethyl)aminomethane AppliChem GmbH (Darmstadt, Germany) 
Triton X-100 Carl Roth GmbH + Co. KG (Karlsruhe, 
Germany) 
Trypan Blue AppliChem GmbH (Darmstadt, Germany) 
Trypsin / EDTA solution (for cell culture) PAA Laboratories GmbH (Pasching, 
Austria) 
Tween 20 Carl Roth GmbH + Co. KG (Karlsruhe, 
Germany) 
Urea AppliChem GmbH (Darmstadt, Germany) 
X-Ray Developing solution Calbe Chemie GmbH (Calbe, Germany) 
X-Ray Fixing solution Calbe Chemie GmbH (Calbe, Germany) 
Table 3: List of used chemicals 
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3.1.2 Primary Antibodies 
 
Name Supplier 
Karyopherin beta Calbiochem; Merck Chemicals 
Vimentin Novus Biologicals 
Visfatin Santa Cruz Biotechnology, INC. 
Heat shock protein 27 Santa Cruz Biotechnology, INC. 
Phosphorylated heatshock protein 27 Santa Cruz Biotechnology, INC. 
Serine protease inhibitor B1 Santa Cruz Biotechnology, INC. 
Proteinase 3 Santa Cruz Biotechnology, INC. 
Cathepsin G Biomol International, LP 
Extracellular-signal regulated protein kinase Cell Signaling Technology®  
Rat sarcoma (protein) Cell Signaling Technology®  
Rat fibrosarcoma/ rapidly growing fibrosarcoma 
(protein) 
Cell Signaling Technology®  
Rat fibrosarcoma/ rapidly growing fibrosarcoma 
(protein) 
Cell Signaling Technology®  
Rat fibrosarcoma/ rapidly growing fibrosarcoma 
(protein) 
Cell Signaling Technology®  
Protein kinase B Cell Signaling Technology®  
Androgen receptor Santa Cruz Biotechnology, INC. 
Progesterone receptor Santa Cruz Biotechnology, INC. 
KH-type splicing regulatory protein Abnova Corporation 
Cyclooxygenase-1 Biozol Diagnostica Vertrieb 
GmbH 
Cyclooxygenase-2 Enzo® Life Sciences 
Table 4: List of used primary antibodies 
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3.1.3 Secondary Antibodies 
 
Name Supplier 
Anti-goat IgG FC Rockland Inc. 
Anti-mouse IgG FC specific Sigma-Aldrich 
Anti-rabbit IgG (whole molecule) Sigma-Aldrich 
Anti-goat IgG (whole molecule) Sigma-Aldrich 
Anti-rabbit IgG (whole molecule) Sigma-Aldrich 
Anti-chicken IgY (IgG) (whole molecule) Sigma-Aldrich 
Anti-mouse IgG (whole molecule) Sigma-Aldrich 
Table 5: List of used secondary antibodies 
 
3.1.4 Recombinant proteins 
 
Name Supplier 
Visfatin Randox Laboratories Ltd. 
HSP27 Biomol GmbH 
Table 6: List of used recombinant proteins 
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3.2 Methods 
 
3.2.1  Isolation of primary human blood cells (PMNL, PBMC, monocytes and 
platelets) 
 
Venous blood was collected from adult healthy volunteers, with consent, and subjected 
to centrifugation (4000 × g/20 min/20 °C) for preparation of leukocyte concentrates 
(Blood Center, University Hospital Tuebingen, Germany). Leukocyte concentrates from 
different donors were pooled and diluted 1:1 (v/v) with PBS buffer (1 mM KH2PO4, 3 
mM Na2HPO4, 150 mM NaCl, pH 7.4). PMNL, PBMC and platelets were isolated by 
dextran sedimentation  (5% (w/v) dextran in ice cold PBS for 45 min at RT) followed 
by centrifugation on lymphoprep cushions (1000 × g, 10 min, RT, without brake). 
PMNL, PBMC and platelets were collected by taking respective fractions after centrifu-
gation (1000 × g, 10 min 4°C for PMNL and PBMC; 2000 × g, 10 min, 4°C for 
platelets). 
 
For isolation of PMNL, hypotonic lysis of erythrocytes was performed as described 
[136]. Cells were washed two times prior use by addition of PBS buffer pH 7.4 and cen-
trifugation. 
 
For isolation of monocytes, the mononuclear cell fraction (PBMC) was washed and 
resuspended in RPMI 1640 medium supplemented with 2 mM glutamine, 100 µg/ml 
streptomycin, 100 U/ml penicillin, 10% fetal calf serum (FCS). Cells were plated at a 
density of 2 × 107 cells/ml in culture flasks for 2 h (37°C, 6% CO2). Non-adherent cells 
(i.e., lymphocytes) were removed by gentle washing with PBS buffer. Adherent mono-
cytes were harvested by scraping and resuspended in PBS or PG buffer (PBS containing 
0.1% (w/v) glucose) respectively. 
 
Cells were counted after addition of trypan blue solution 1:1 (v/v) (0.2% (w/v) Trypan 
blue, 0.9% (w/v) NaCl) under a light microscope using a “Bürker” haemocytometer.  
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3.2.2 Culture of immortalised cells 
 
All cell lines were cultured at 37 °C and 6% CO2 in incubators with saturated humidity. 
Cells were cultured according to supplier instructions as followed (Tab. 7). 
 
Cell line Medium Splitting conditions 
LNCap RPMI 1640 medium containing 10% heat 
inactivated FCS, 100 U/ml penicillin, 100 
µg/ml streptomycin, 10 mM Hepes and 1 
mM sodium pyruvate 
Subconfluent cultures (70 - 
80%) were split 1:5 using 
0.05% trypsin and 0.02% 
EDTA in PBS buffer 
Jurkat A3 RPMI 1640 medium containing 10% heat 
inactivated FCS, 100 U/ml penicillin, 100 
µg/ml streptomycin 
Cells were split 1:5 at a 
density of 8 × 105 cells/ ml 
HeLa RPMI 1640 medium containing 10% heat 
inactivated FCS, 100 U/ml penicillin, 100 
µg/ml streptomycin 
Subconfluent cultures (70 - 
80%) were split 1:8 using 
0.05% trypsin and 0.02% 
EDTA 
PC12 Dulbecco´s Eagle Medium (DMEM) con-
taining 10% heat inactivated FCS, 5% heat 
inactivated horse serum, 100 U/ml penicil-
lin and 100 µg/ml streptomycin 
Subconfluent cultures (80 - 
90%) were split 1:5 
Table 7: Conditions for cultivation of immortalised cells 
 
 
3.2.3 Preparation of cell lysates 
 
3.2.3.1 Preparation of whole cell lysates 
 
Whole cell lysates were prepared by addition of 1 ml lysis buffer (50 mM Hepes pH 
7.4, 200 mM NaCl, 1 mM EDTA, 1% Triton® X-100, 10 µg/ml leupeptin, 2 mM PMSF, 
120 µg/ml soybean tripsin inhibitor (STI)) per g drained cell pellet, following 3 × 10 sec 
sonification. Lysed cells were centrifuged (15,000 × g, 1 h, 4 °C) to remove cell debris 
and the supernatants were used for fishing experiments. 
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3.2.3.2 Isolation of soluble proteins 
 
Soluble proteins were isolated by addition of 1 ml lysis buffer (50 mM Hepes pH 7.4, 
200 mM NaCl, 1 mM EDTA, 0.1% Triton® X-100, 50 µl P8340 protease inhibitor cock-
tail) per ml cell pellet following 3 x 10 sec sonification. Lysed cells were centrifuged 
(100,000 × g, 1 h, 4°C) to remove cell debris. The supernatant containing solubilised 
proteins was taken for fishing experiments. 
 
 
3.2.3.3 Preparation of E. coli lysate 
 
To prepare E. coli lysate, E. coli (BL21 strain, from a glycerol stock stored at -80°C) 
were added to 20 ml of LB medium (0.5% yeast extract, 1% NaCl, 1% peptone) and 
incubated for 24 h at 37 °C on a shaker. Then, 5 ml of cell suspension were added to 
500 ml fresh LB media and incubated for additional 24 h at 37 °C. 
Cells were harvested by centrifugation (7,700 × g, 15 min, 4 °C) and lysed by addition 
of equal volumes of lysis buffer to the pellet and subsequent sonification (3 × 15 sec) 
(Branson B-12, Branson Ultrasonics Corporation, Danbury, CT). After centrifugation 
(40,000 × g, 20 min, 4 °C), the supernatant was collected and protein concentration was 
set to 1 mg/ml by adding appropriate volumes of lysis buffer. 
 
 
3.2.4 Immobilisation of small molecule ligands to insoluble matrices (beads) 
 
All resins where prewashed with 3 × 5 ml Milli-Q water and with 1 × 5 ml of the ligand 
solution solvent on a G4 glass filter crucible. For immobilisation, ligand solution (300 
µmol in 2 ml solvent) and 1.5 mmol carbodiimide were added to 1 ml prewashed 
amino-functionalised methacrylic acid resin (Toyopearl AF-Amino-650M, Tosho Bio-
science). The reaction was performed at room temperature (RT) at pH 4.5 over night. 
Remaining free amino groups of the resin were blocked with acetic acid (150 µmol, 
with 1.5 mmol N,N-diisopropylcarbodiimide (DIC) at RT over night). Between every 
reaction step, the resin was washed with 20 ml solvent (depending on the solubility of 
the ligand, see below). 
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When the reaction was complete, the resin was washed 3 times with 5 ml solvent (de-
pending on the solubility of the ligand, see below) and then 3 times with 5 ml acetate 
buffer (0.1 M sodium acetate, 0.1 M acetic acid, pH 4, 0.5 M NaCl) and Tris buffer (0.1 
M Tris-HCl pH 8, 0.5 M NaCl), alternately, to remove ionic-bound ligand. The beads 
were finally washed with 5 ml 20% (v/v) ethanol and stored at 4 °C in 20% (v/v) etha-
nol until use. 
Depending on the solubility of the ligand, the following solvents where used: Dioxane 
(50 – 100% (v/v)), DMF, THF, methanol. Water soluble carbodiimides such as 1-(3-
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) where used if water 
was necessary as solvent, otherwise N,N-dicyclohexylcarbidiimide (DCC) or DIC 
where used. An additional washing step with methanol after the coupling reaction was 
performed to remove the corresponding urea derivative of the carbodiimide, when un-
polar carbodiimides (such as DCC or DIC) were used. 
 
For detailed immobilisation conditions of selected small molecule ligands, see results 
part 4.2. 
 
 
3.2.4.1 Immobilisation strategies for ligands 
 
Depending on the chemical nature and presence of functional residues, the following 
reactions were used to immobilise small molecules. 
 
3.2.4.1.1  Immobilisation of ligands on amino functionalised matrices over car-
boxylic acid residues 
Coupling of molecules containing carboxylic residues to amino functionalised matrices 
is a standard reaction performed in the synthesis of peptides via a solid phase approach 
(Fig. 13) [137-138]. Reactions were performed with a 10- to 100 fold excess of ligand 
(calculated in relation to free binding sides of the matrix). Times and conditions of the 
reaction were adapted to the requirement of each ligand, on the base of the respective 
chemistry. Thus, for compounds showing a good solubility in aqueous systems (e.g. 
50% or more water), the reaction was performed using agarose beads and required a 
water soluble carbodiimide such as EDC. For lipophilic compounds (such as steroids or 
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terpenes), organic solvents (preferable dioxane, THF or DMF) and methacrylic acid 
resins were used, and DIC was applied as carbodiimide. 
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Figure 13: Immobilisation of ligands containing carboxy residues to amino activated matrices 
 
3.2.4.1.2  Immobilisation of ligands on carboxylic acid functionalised matrices 
over amine residues 
 
Immobilisation of molecules containing amine residues to carboxylic acid functional-
ised matrices was performed under the same conditions as described in (3.2.4.1.1). 
 
 
3.2.4.1.3  Immobilisation of ligands to epoxy-functionalised matrices 
 
Ligands containing –NH2 or –OH residues were immobilised by incubating appropriate 
amounts of solubilised ligand with beads, under alkaline conditions (Fig. 14). In gen-
eral, over night incubation at RT and pH values between 9 and 13 were required for a 
sufficient coupling. 
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Figure 14: Immobilisation of ligands containing hydroxy and amino residues to epoxy-activated 
matrices. R could be –OH, -NH2 or –SH. 
 
 
3.2.4.1.3.1 Immobilisation of Acetaminophen (ACAP) 
 
A.) N-glutaroyl-phenolamine and glutaric acid were immobilised by dissolving 74.3 
mg (333 µmol) N-glutaroyl-phenolamine and 43.6 mg (333 µmol) glutaric acid in 10 ml 
40% (v/v) dioxane. 290 mg 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochlo-
ride and 10 µl HCl (1 M) were added. The coupling reaction was performed as de-
scribed in chapter 3.2.4. 
 
B.) Acetaminophen/ Phenol immobilisation: immobilisation of ACAP and phenol to 
epoxy activated beads was performed by dissolving 1 mmol of ACAP and phenol in 
dioxane respectively. 75 mg beads were given to this solution and the pH value was 
adjusted to pH 14 by addition of 10 µl NaOH (10 M). 
 
C.) Aminophenol/ Aniline: Aminophenol and aniline were immobilised by dissolving 
109.1 mg (1 mmol) Aminophenol and 93.14 mg aniline in 2 ml dioxane respectively. 
The pH value was adjusted by addition of 20 µl HCl 2 M. After addition of 1 ml 
Toyopearl® AF 650M carboxy slurry the reaction was started by addition of 30 mg 
EDC. 
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3.2.5 Fishing experiments / pull-down assays 
 
3.2.5.1 Pull down assay of proteins from cell lysates 
 
For pull-down assays, 50 µl beads (corresponding to 100 µl of 50% (v/v) bead slurry) 
were used. Beads were washed 3 times by centrifugation (7000 × g, 5 min, 4 °C for 
Sepharose® beads; 5000 × g, 3 min, 4° C for polyacrylic acid beads) and were resus-
pended in 500 µl binding buffer (different binding buffers were used, depending on the 
experimental requirements, see results). Incubation of the beads with the cell lysate was 
performed for 4 h at 4 °C on a rotator in 750 µl binding buffer. 
All steps regarding derivatisation or incubation of beads were performed on a tube rota-
tor to ensure appropriate agitation and to prevent sedimentation of the beads during 
these steps. 
 
3.2.5.2 Pull down of recombinant proteins 
 
For pull-down of isolated recombinant proteins, beads where prepared as described in 
(3.2.5.1). To prevent adhesion of the isolated protein to plastic surfaces or unspecific 
binding to the beads, E. coli lysate or BSA (0.25 mg total protein content in 750 µl as-
say volume) were used.  
 
3.2.5.3 Elution of fished proteins 
 
3.2.5.3.1 SDS elution 
 
The beads were washed 3 times with 500 µl binding buffer. Fished proteins were eluted 
by addition of 50 µl SDS-PAGE loading buffer (20 mM Tris pH 8.0, 2 mM EDTA, 
0.5% (w/v) SDS, 10% (v/v) 2-mercaptoethanol) to 50 µl beads and 5 min incubation at 
95 °C. Eluted proteins were separated from the beads by centrifugation (7000 × g, 5 
min, 4°C) and then analysed (see 3.2.6). 
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3.2.5.3.2 Urea elution 
 
The beads were washed 3 times with 500 µl binding buffer. Fished proteins were eluted 
by addition of 50 µl 4 M urea to 50 µl beads and 30 min incubation at 4°C. Eluted pro-
teins were separated from the beads by centrifugation (7000 × g, 5 min, 4°C) and incu-
bated for 5 min at 96 °C after addition of 50 µl SDS-PAGE loading buffer (20 mM Tris 
pH 8, 2 mM EDTA, 0.5% (w/v) SDS, 10% (v/v) 2-mercaptoethanol). 
 
3.2.5.3.3 Elution via cleavage of photoreactive linker systems 
 
For detailed conditions of protein elution via cleavage of photoreactive linker systems 
see Results part (4.1.5.1). 
 
 
3.2.6 Protein analytics 
 
3.2.6.1 One dimensional gel electrophoresis (SDS-PAGE) 
 
For electrophoretic separation, protein samples were mixed with equal volumes of SDS 
buffer (20 mM Tris-HCl, pH 8, 2 mM EDTA, 5% (w/v) SDS, 10% (v/v) 2-
mercaptoethanol), heated for 5 min at 96 °C and then 2 µl bromphenol blue solution 
(50% (v/v) glycerol, 0.1% (w/v) bromophenol blue) were added to 10 µl sample. Pro-
teins were separated by SDS-PAGE using self cast gels with 8 - 14% (v/v) acrylamide 
(according to the protein size). For a maximum resolution, constant currents of 90 V for 
the stacking-gel and 120 V for the separation-gel were applied. 
 
3.2.6.2 Western blot analysis 
 
Proteins were blotted (tank blotting method) from polyacrylamide gels to nitrocellulose 
membranes (90 V const., 90 min, in transfer buffer containing 48 mM Tris, 40 mM 
Glycine mM, 0.1 mM SDS, 20% (v/v) methanol). Correct loading of gels and transfer 
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of proteins were confirmed by Ponceau S staining (0.1% (w/v) Ponceau S, 5% (v/v) 
acetic acid for 5 sec). 
Membranes were blocked with BSA blocking buffer (50 mM Tris-HCl, pH 7.4, 100 
mM NaCl, 0.1% Tween 20, 5% (w/v) BSA) for 1 h at RT, washed with TBS buffer (50 
mM Tris-HCl, pH 7.4, 100 mM NaCl ) for 10 min at RT and then incubated with the 
respective primary antibody overnight at 4 °C. Antibodies were diluted in BSA blocking 
buffer, as indicated.  
 
3.2.6.2.1 NBT/BCiP development of membranes 
 
The membranes were washed (3 × 10 min) with TBS buffer and incubated with a 
1:1000 dilution of alkaline phosphatase-coupled secondary antibodies for 1 h at RT. 
After washing 3 × 10 min with TBS buffer, 1 × 10 min TBST buffer ((50 mM Tris/HCl, 
pH 7.4, 100 mM NaCl, 0.1% (v/v) Tween 20), 1 × 10 min in detection buffer (100 mM 
Tris/HCl, pH 9.5; 100 mM NaCl, 5 mM MgCl2), proteins were visualised by incubation 
of membranes with 0.4 mM nitro blue tetrazolium chloride (NBT) and 0.75 mM 5-
bromo-4-chloro-3-indolyl phosphate (BCiP) in detection buffer. 
 
3.2.6.2.2 ECL development of membranes 
 
The membranes were washed (3 × 10 min) with TBST buffer and incubated with a 
1:10,000 dilution of horseradish peroxidase (HRP)-conjugated secondary antibodies 1 h 
at RT. After washing (2 × 5 min, 1 × 15 min, 2 × 5 min with TBST buffer respectively), 
proteins were visualised by addition of HRP-substrate (AmershamTM ECL Western 
blotting detection reagent, GE Healthcare). Chemoluminescence films (Amersham Hy-
perfilmTM ECL) where exposed for the indicated times and developed using an X-Ray 
table-top processor (CP 1000 AGFA Healthcare N.V., Mortsel, Belgium) 
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3.2.6.2.3 ETTANTM DIGE development of membranes 
 
The membranes were rinsed two times with TBST buffer and subsequently washed (2 × 
5 min) with TBST buffer. Afterwards, the membranes were incubated with ECL Plex 
CyDyeTM-conjugated secondary antibodies (1 h, RT, Cy3-conjugated anti-mouse dilu-
tion: 1:2500 in TBS buffer; Cy5-conjugated anti-mouse dilution: 1:4000 in TBS buffer). 
After washing (3 times for 5 sec plus 4 × 5 min with TBST buffer in the dark) the mem-
branes were rinsed with TBS buffer and dried at 37 °C for 1 h. 
Bands were visualised using an ETTANTM DIGE Imaging system (GE Healthcare), us-
ing Cy3 (excitation filter: 540 nm; emission filter: 595 nm) and Cy5 (excitation filter: 
635 nm; emission filter: 680 nm) channels. Incubation with CyDyeTM labelled antibod-
ies and following steps were performed in the dark to avoid bleaching of the fluoro-
phoric group. 
 
 
3.2.6.3 Silver staining 
 
Silver staining was performed by fixing the gels immediately after the electrophoretic 
run in fixing solution (45% (v/v) methanol, 45% (v/v) H2O, 5% (v/v) acetic acid) for 30 
min. Gels were then washed for 30 min in water and sensitised by addition of Na2S2O3 
solution (1 mg/ml) for two minutes. After two more washing steps (1 min, each) with 
Milli-Q water, the staining solution (AgNO3, 1 mg/ml) was added for 30 min. Again, 
two washing steps with water (1 min, each) were performed and then the developing 
solution (2.5% Na2CO3, 0.03% formalin in H2O) was added for the time required to 
reach an optimal intensity of the staining. The staining reaction was stopped by a 
quenching step using 1% (v/v) acetic acid. Prior further steps, gels were washed with 
water for 10 min.  
 
All solutions were prepared using Milli-Q water. All steps were performed on an orbital 
shaker at RT. Staining and sensitising solutions were prepared freshly and kept on ice 
until use. For large 18 × 20 cm gels and 2D gels, sensitising and staining steps were 
performed on ice.  
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3.2.6.4 CyDyeTM labelling for differential gel electrophoresis (DIGE) 
 
For 2D-DIGE, proteins were eluted with 4 M urea pH 8.5. The protein concentration 
was determined using an urea-compatible protein determination kit (BioRad DC Assay-
Kit). For preparation of the CyDyeTM working solution, 2 mM CyDyeTM stock solution 
was diluted 1 to 2.5 with 3 µl water-free DMF (<0.005 ppm water). The pH was ad-
justed between 8.5 and 9.5 by adding 50 mM NaOH. For the coupling of the CyDyeTM 
to the proteins, CyDyeTM working solution (1 µl for 10 µg protein) was added to the 
samples and incubated for 30 min at 4 °C. The reaction was stopped by addition of 1 µl 
10 mM lysin. CyDyeTM labelled samples were stored at -80 °C until the isoelectric fo-
cussing (IEF). 
 
3.2.6.5 Isoelectric focussing (IEF) 
 
IEF was performed on 17 cm immobilised pH gradient (IPG) strips with a non linear pH 
gradient from pH 3 to pH 10 (Ready StripTM IPG Strip). Proteins were diluted with PCT 
buffer (8 M urea, 2 M thiourea, 4% (w/v) chaps, ampholyte pH 3-10 0.7% (v/v), dithio-
threitol (DTT) 65 mM, 10 µg/ml bromophenol blue). To prevent protein degradation by 
proteases, 50 µl P8340 protease inhibitor cocktail per gram protein was added to the 
sample. 300 µl sample solution containing up to 300 µg labelled and multiplexed pro-
teins was pipetted into a 17 cm focussing tray. An IPG strip was placed on the sample to 
rehydrate with the sample solution for 12 h at 50 V and 10 °C (BioRad Protean® IEF 
cell, Herecules, CA). 
 
step voltage [V] time slope 
1 0-250 1 min linear 
2 250 2 h linear 
3 250-500 1 min linear 
4 500 2 h linear 
5 500-1000 1 min linear 
6 1000 1 h linear 
7 1000-4000 1 h linear 
8 4000 2 h linear 
9 4000-10,000 2 h linear 
10 10,000 30 kVh linear 
Table 8:Voltage slope for IEF with 17 cm IPG strips 
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After rehydration, electrode wicks were moistened with 5 µl PCT-buffer and placed on 
the electrodes. IEF was performed using the following voltage conditions (Tab. 8). 
Focussed stripes where stored at -80°C until development of the second dimension. 
 
For development of the second dimension, a SDS-PAGE was performed to separate 
proteins on the base of their molecular weight. IPG-strips were equilibrated by incuba-
tion for 2 × 7 min in equilibration buffer I (6 M urea, 4 (w/v) SDS, 0.05 M tris pH 8.8, 
30 (v/v) glycerol, 1% (v/w) DTT), 2 × 7 min in equilibration buffer II (6 M urea, 4 
(w/v) SDS, 0.05 M Tris pH 8.8, 30 (v/v) glycerol, 4% (w/v) iodoacetamide), and 1 × 10 
s in SDS-PAGE running buffer (200 mM glycine, 25 mM Tris, 3 mM SDS). The IPG 
strip was placed on top of an 18 × 20 cm polyacrylamide gel containing 12% acryla-
mide overlayed by a 2 cm stacking gel. The IPG-strip was ingrained into an agarose gel 
(0.5% (w/v) agarose, 0.001% bromophenol blue in SDS-PAGE running buffer (25 mM 
Tris, 190 mM glycine, 3.5 mM SDS). For evaluation of molecular weights of proteins, a 
filter paper (5 mm diameter) was moistened with 5 µl of protein markers (peqLab, 
peqGOLD IV) and ingrained together with the IPG-strip. Gels were developed with a 
constant current of 16 mA for the stacking gel and 24 mA for the separation gel for a 
run time of about 8 h (BioRad PowerPacTM HV, Hercules, CA). 
 
All urea containing buffers were purified from carbamoylated contaminations and salt 
impurities by incubating with ion exchange resin (BioRad AG® 501-X8 Resin). Appro-
priate amounts of AG 501-X8 ion exchange resin were determined by observation of a 
colour change from gold/yellow to transparent/colourless, due to depletion of the ion 
exchange capacity. 
 
 
3.2.6.6 Acquisition of results 
 
Silver stained gels and X-ray films of ECL-developed Western blot membranes were 
acquired with a CCD camera system (CabUVis, Hitachi HV-C20M 3CCD, Sarstedt AG 
Co., Nümbrecht, Germany). NBT/BCiP developed Western blots were digitised with a 
common flat bed scanner. 
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DIGE pictures were obtained by an ETTANTM DIGE Imager system (GE Healthcare) 
and evaluated via ImageQuantTM TL software. Appropriate dyes were scanned in their 
corresponding channels (Tab. 9). Required exposure times were set to 0.040 – 0.400 sec 
for Western blot experiments, depending on the signal intensities, and to 1.000 – 4.000 
sec (= highest possible exposure time) for 2D DIGE gels. 
 
Dye Exication filter Emission filter 
Cy 2 480 nm 530 nm 
Cy 3 540 nm 595 nm 
Cy 5 635 nm 680 nm 
Table 9: Exication and emmision wavelengths of the ETTAN DIGETM channels 
 
Spots on scanned 2D-DIGE gels were detected using the DeCyder 7.0 software. DeCy-
der 7 algorithm was used to calculate appropriate spot values. The threshold was set as 
2.0. Spots exceeding a slope of 1.0 were considered artificial. 
 
MS analytics of fished proteins was done in cooperation with the Proteom Center at 
Univ. Tuebingen via in-gel digestion and nanoflow liquid chromatography tandem MS 
(nano-LC-ESI-MS/MS) on a QSTAR Pulsar hybrid qTOF mass spectrometer (AB-MDS 
Sciex) as described previously [139]. Bioinformatic analysis of the identified peptides 
was subsequently done with Matrix Science Mascot. 
 
 
3.2.7 Functional enzyme assays 
 
3.2.7.1 Determination of phosphorylated proteins 
 
Isolated neutrophils (107 cells /100 µl PGC buffer (PBS containing 0.1% (w/v) glucose 
and 1 mM CaCl2) were incubated with the indicated compounds at 37 °C for the indi-
cated time. The reaction was stopped by addition of 100 µl of 2×SDS buffer (20 mM 
Tris pH 8, 2 mM EDTA, 0.5% SDS, 10% 2-Mercaptoethanol) and incubated for 6 min 
at 95°C. After sonification for 10 sec, total cell lysates were analysed for ERK1/2, 
phosphorylated ERK1/2 (Thr-202/Tyr-204), phosphorylated AKT (Ser473), HSP27 and 
phosphorylated HSP27 (Ser82) by SDS-PAGE and Western blotting. 
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3.2.7.2 Serine protease activity assays 
 
3.2.7.2.1 Proteinase 3 (PR3) activity assay 
 
Proteinase 3 purified enzyme (0.1 µg) was diluted in 100 µl assay buffer (0.1 M Mops, 
0.5 M NaCl, 0.1 mM 5,5´-dithiobis-(2-nitro-benzoic acid), pH 7.5) in a 96 well plate. 
The enzyme was preincubated with the indicated compounds for 15 min at RT. The 
enzymatic reaction was started by addition of 0.1 mM substrate (Boc-Ala-Ala-Nva-
SBzl) in 100 µl assay buffer. Enzyme activity was measured by detection of the reduced 
cosubstrate (2-nitro-5-thiobenzoate dianion) on a microplate reader (VersaMaxTM, Mo-
lecular Devices Inc., Sunnyvale, CA) at 410 nm for 1 h at RT. 
 
 
3.2.7.2.2 Cathepsin G (CG) activity assay 
 
CG was freshly isolated from PMNL (2.5 × 107 cells/ml in PGC buffer) by stimulation 
with 10 µM cytochalasin B and 2.5 µM fMLP for 5 min at 37 °C and subsequent cen-
trifugation (1200 × g, 5 min, 4°C). The supernatant (10 µl/sample) was used as source 
of CG and added to 180 µl assay buffer (0.1 M Hepes pH 7.4, 0.5 M NaCl). The en-
zyme was preincubated with the indicated inhibitors for 15 min at 37 °C. The enzymatic 
reaction was started by addition of CG substrate (1 mM N-Suc-Ala-Ala-Pro-Phe-pNA) 
and the conversion of the substrate was directly measured by detection of the proteolytic 
product (p-nitrophenol) on a microplate reader (VersaMaxTM, Molecular Devices Inc., 
Sunnyvale, CA) at 410 nm for 1 h at RT. 
 
Compounds were solubilised in ethanol or DMSO. The final concentration of solvents 
in the assay was kept below 0.1% (v/v) for 3.2.7.1 and 1% (v/v) for 3.2.7.2. 
 
 4 Results   43 
4 Results 
 
4.1 Development of methods to improve fishing approaches 
 
4.1.1 Evaluation of different matrix types: 
 
A summary of the chemical composition of different matrix types is given in the intro-
duction (1.2.2). In our experiments, agarose beads show an insufficient chemical resis-
tance against organic solvents limiting their application and the possibilities of modifi-
cation reactions. While agarose beads get partially solubilised or show a dramatic 
change in their structure using moderately unpolar solvents such as dioxane, methanol, 
THF or DMF, methacrylic acid matrices turned out to be stable under these conditions. 
Strongly unpolar aromatic solvents, such as toluene, as well as extreme pH values and 
high temperatures facilitate solubilisation of these beads. However, methacrylic acid 
matrices afford the widest range of possibilities and were therefore used in subsequent 
experiments. 
 
4.1.2 Generation of carboxymethoxylamine beads for immobilisation of ligands 
via keto- or aldehyde groups. 
 
Since there are no commercially available matrices to immobilise ligands via keto- or 
aldehyde residues to beads, we established an approach to derivatise existing matrix 
types to allow subsequent immobilisation of aldehydes and ketones II. 
For this purpose, N-boc-carboxymethoxylamine was covalently coupled to amino func-
tionalised beads under standard coupling conditions (see 3.2.4). After deprotection of 
the oxime group (10% (v/v) TFA, on, RT) the ligand can be coupled under mild reac-
tion conditions (MeOH, Pyridin, RT, on) to the beads (Fig. 15). 
 
                                                 
II
 The development of carboxymethoxylamine activated beads was done in cooperation by dipl. chem. M. 
Golkowski and the group of Prof. Dr. T. Ziegler, Institute of Organic Chemistry, University Tübingen 
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Figure 15: Matrix surface derivatisation for aldehyde and ketone immobilisation. N-boc-
carboxymethoxylamine (1) is coupled under standard conditions (I) (DIC, RT, on in dioxane, pH 4) 
to the amino functionalised matrix (2). The Boc group was removed by addition of TFA (10 % 
(v/v), RT, on) (II) to receive the free methoxyl function (4). The ligand was used in a 1:1 ratio and 
coupled by addition of two equivalents pyridine in MeOH at RT over night (III). 
 
Testosterone was used as model compound for this derivatization strategy since it pos-
sesses one single keto group and thereby offers the possibility for a selective immobili-
sation. Successful immobilisation of testosterone was controlled by addition of 35% 
(v/v) ethanolic sulfuric acid and subsequent heating (75°C, 10 min) which leads to a 
fluorescent product. Fluorescence of the steroid was detected by UV light exposure at 
366 nm. Neither the beads alone nor the carboxymethoxylamine derivatised beads 
showed any fluorescence. A solution of testosterone as positive control as well as tes-
tosterone coupled to the beads show distinct fluorescence as result of a successful ligand 
coupling (Fig. 16). 
 
Toyopearl AF 650 M Amino
Toyopearl CMO Functionalised
Toyopearl CMO coupled Testosterone
Testosterone solution
 
Figure 16: Verification of testosterone immobilisation on carboxymethoxylamin (CMO)-activated 
beads. Testosterone shows fluorescence after treatment with ethanolic H2SO4 35% and subsequent 
heating at 75°C for 1 h. A solution of testosterone in MeOH as well as the testosterone coupled 
CMO-beads show  fluorescence, whereas CMO-activated or unmodified beads themselves are not 
fluorescent. 
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Further studies in cooperation with M. Golkowski (Dept. of Organic Chemistry, Univ. 
Tuebingen) showed that other compounds like ketoprofen as well as complex structures 
like erythromycin can be immobilised selectively and without derivatization reaction 
using this strategy (data not shown). 
 
 
4.1.3 Evaluation of fishing conditions 
 
For the evaluation of the fishing conditions, a huge number of buffers containing differ-
ent types and quantities of salts or detergents were tested. However, buffer systems con-
taining PBS or Hepes as buffer substance, a pH-Value of 7.4 and 0.9% NaCl turned out 
to be sufficient. The use of Hepes resulted in a higher number of bound protein, but 
since it is known to form radicals [140] it was substituted by PBS for experiments 
where extensive UV radiation was applied. 
Addition of non ionic detergents in concentrations up to 1% reduced unspecific protein 
binding. Overnight incubation with cell lysates (pre-cleared by ultracentrifugation) led 
to the best fishing results. 
 
 
4.1.4 Evaluation of elution conditions 
 
In order to evaluate various elution conditions, experiments were performed using im-
mobilised ACAP that was incubated with PBMC and PMNL cell lysates. Elution using 
SDS-buffers results in a large number of eluted proteins that exceed the separation ca-
pacity of a standard 8 × 6 cm polyacrylamide gel. Elution using NaCl (1 M) was less 
stringent but not more specific. Thus, the analysis of proteins is limited to the estimated 
50 most abundant proteins. Using a solution of ACAP (50 mM) to elute proteins fished 
by ACAP in a competitive way leads to very low amounts of eluated proteins (Fig. 17). 
 
46    4 Results 
SDS
elution
NaCl
elution
ACAP
elution
AC
AP
Ct
rl. AC
AP
Ct
rl. AC
AP
Ct
rl.
 
Figure 17: Evaluation of different elution conditions. Electrophoretical separation of fishing-eluates 
derived by elution of ACAP-matrices after incubation with lysates of PMNL using SDS, NaCl and 
ACAP buffer and detection of the proteins by silver staining.  
 
4.1.5 Improvement of the target-fishing approach 
 
The major disadvantage of the target-fishing is the high number of unspecific bound 
proteins. Two different strategies were followed in order to improve this approach. On 
the one hand, an UV light cleavable linker system was developed to by-pass unspecific 
binding events. On the other hand, the electrophoretic separation capacity was improved 
by using a 2D-DIGE approach. 
 
 
4.1.5.1 Development of a photoreactive linker system 
 
The synthesis of the o-nitrophenyl linker was done according to Holmes et at 1996 [21, 
141] in cooperation with Thomas Kutter (Dept. of Organic Chemistry, Univ. Tuebin-
gen) (Fig. 18). 
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Figure 18: Synthesis of the Boc protected nitrobenzylic photoreactive linker system with C5 spacer. 
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Modifications of known linker systems were needed in order to achieve a better solubil-
ity and biocompatibility. Therefore, the photoreactive core of the molecule was re-
tained, whereas subsequent changes of alkyl chain length and the protection group were 
tested III. A tert-butoylxycarbonyl- (Boc) protected o-nitrobenzylic linker with a C5 
chain spacer turned out to be optimal in immobilisation- and cleavage reactions. 
 
 
4.1.5.2  Development of an immobilisation strategy for UV light cleavable linker 
systems 
 
The Boc-protected linker was immobilised using standard peptide chemistry [137-138] 
(3.2.4). To ensure that the ligand is only bound via the photoreactive linker and not di-
rectly to the beads, the immobilisation was performed in four steps: (i) immobilisation 
of the linker to the functionalised beads, (ii) blocking of remaining functional groups, 
(iii) removal of the Boc-group and (iv) releasing the ligand. 
The immobilisation of the linker, the ligand and the blocking of remaining free amino 
groups was performed in three steps using three times the same reaction (Fig. 19). For 
the immobilisation, the linker solution (300 µmol in 2 ml DMF) and 1.5 mmol diisopro-
pylcarbodiimide (DIC) were added to 1 ml pre-washed amino-functionalised 
methacrylic acid resin (Toyopearl® AF-Amino-650M; Tosho Bioscience). The reaction 
was performed at room temperature and pH 4.5 over night. Remaining free amino 
groups of the resin were blocked with acetic acid (150 µmol, with 1.5 mmol DIC at 
room temperature over night). Afterwards the boc group was removed (10% TFA in 
H2O, 90 min at RT) to receive the free amino group of the linker. The ligand was cou-
pled by adding 2 ml ligand solution (330 µmol ligand, 1.5 mmol DIC) to the resin and 
incubating it over night at pH 4.5 and room temperature. Washing steps were performed 
between every reaction step by washing the resin with 20 ml DMF on a G4 glass filter 
crucible. 
 
                                                 
III
 Synthesis of putative UV-linker molecules was done in cooperation by dipl. chem. T. Kutter and the 
group of Prof. Dr. T. Ziegler, Institute of Organic Chemistry, University Tübingen 
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Figure 19: Immobilisation strategy for photoreactive linker systems. The Boc protected linker (2) is 
coupled under standard conditions (I) (DIC, RT, on in dioxane, pH 4) to the amino activated matrix 
(PAA, 1). Remaining free amino groups of compound 3 are blocked with acetic acid (II) (DIC, RT, 
on in dioxane, pH 4). The protection group of (4) was removed by addition of TFA (10% (v/v), RT, 
on) (III) and the ligand was then coupled in the last step (IV). 
 
4.1.5.3 Fishing conditions for UV light cleavable linker systems 
 
A standard buffer system used for pull-down experiments and protein fishing is a 
HEPES binding buffer composed of 50 mM Hepes pH 7.4, 200 mM NaCl, 1 mM 
EDTA, 1% (v/v) triton® X-100. Since HEPES is known to form radicals [140] we chose 
a phosphate-based buffer system composed of PBS pH 7.4 containing 1 mM EDTA, 
200 mM NaCl, 1% (v/v) triton® X-100 to elute protein via UV light cleavage of the 
linker. 
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4.1.5.4 Elution conditions for UV light cleavable linker systems 
 
Previous works have described the usage of nitrobenzylic linker systems for cleaving 
peptides from a matrix after a solid phase synthesis [21]. In this work cleavage of the 
linker was performed by UV radiation using a 1000 W UV lamp. In our experiments, a 
power of 100 W led to destruction of the proteins due to ionising radiation (Fig. 20). On 
the other hand, UV lamps with a power between 4 W and 16 W and a distinct wave-
length of 366 nm used for TLC plate evaluation were not strong enough to cleave the 
linker system. To combine the benefits of both, the high power of the 100 W UV lamp 
and the distinct wavelength of the low power UV lamps, the filter plates of the low 
power UV lamp were removed and mounted to the 100 W UV lamp. Thus, the high 
energy of the 100 W UV lamp could be used while ionising radiation is refrained by the 
filter plates. 
Elution of proteins by cleavage of the linker was performed in a cooled 24-well plate on 
an orbital shaker. After fishing and subsequent washing procedures 100 µl beads were 
suspended in 100 µl PBS binding buffer and irradiated for 90 min. 
 
A B
 
Figure 20: SDS-PAGE of testosterone fished proteins from PMNL cell lysates with (B) and without 
UV light exposure (A) (1 h, 100 W, 4°C). 
 
To validate the functionality of our UV light cleavable linker system and appropriate 
cleavage conditions, a model system consisting of testosterone as ligand and the andro-
gen receptor (AR) as known target was established. After a protein fishing experiment 
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using LNCap lysate as protein source, the AR is bound to the matrix surface (Fig. 21A). 
Extended blocking approaches as well as stringent washing conditions could not prevent 
the AR matrix interaction (Fig. 21A). 
The use of the UV light cleavable linker system by-passed the AR matrix interaction by 
releasing only proteins that are bound on a ligand that is released after UV irradiation. 
Thus, AR still binds to the matrix but is not eluted whereas testosterone-bound AR can 
be released by cleaving off the testosterone from the matrix (Fig. 21B). 
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Figure 21: (A) Western blot of fishing eluates from testosterone-matrices in LNCap cell lysates with 
different blocking and extended washing conditions. Untreated: fishing performed according to the 
standard protocol (3.2.5); Ethanolamine blocked: Blocking of free primary amino groups by cou-
pling ethanolamine to the matrix; E. coli blocked: E. coli lysate (1 mg/ml protein) was used to block 
protein binding moieties of the matrix; Extended wash 1: Washing steps using alternately 300 fold 
column volume of acetate buffer (pH 4, 0.5 M NaCl) and Tris buffer (pH 8, 0.5 M NaCl); Extended 
wash 2: Washing steps using 300 fold column volume of binding buffer containing 1% Triton® X-
100. (B) Western blot of fishing experiments in LNCap cell lysates using testosterone-matrice with 
UV light cleavable linker: Elution was performed with SDSb or via cleavage of the photoreactive 
linker system. Data shown are representative of at least three independent experiments. 
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4.1.5.5 Establishment of 2D-DIGE for pull down assays 
 
2D-DIGE is a protein separation and detection method with high sensitivity and a high 
resolution. It allows simultaneous quantification of two or more groups of differentially 
labelled proteins. 2D-DIGE was established to compare protein expression patterns of 
different cell types. Therefore, it has to be optimised to comply with the requirements of 
the target-fishing approach. 
Although eluates from target-fishing experiments contain a limited pre-selected number 
of proteins, the sample complexity exceeded the resolution of standard, one dimensional 
gel electrophoresis (Fig. 17). Hence, alternatives to the classical one-dimensional SDS-
PAGE had to be developed and optimised for the analysis of target-fishing eluates.  
 
 
4.1.5.6 Elution conditions for 2D-DIGE 
 
For the 2D-DIGE approach, classical elution conditions with SDS buffers are not suit-
able since SDS masks the isoelectric points of the proteins. Thus, IEF and CyDye com-
patible alternatives had to be found. A buffer containing 4 M urea with pH 8.5 was the 
highest concentration that could be achieved at 4 °C and showed adequate elution 
strength and compatibility with subsequent CyDye labelling reactions. 
 
 
4.1.5.7 Labelling conditions for 2D-DIGE: 
 
Since 2D-DIGE approaches are developed for whole cell lysates, labelling conditions 
for the fishing eluates had to be adopted to the very low protein concentrations and to 
the specific buffer compositions of fishing experiments (detailed labelling conditions 
are described in the methods part). Figure 22A shows the successful labelling of a fish-
ing eluate with Cy5 (lane1/red) and Cy3 (lane 2/ green) and a “one-to-one” mixture of 
sample 1 and 2 in lane 3. As shown in figure 22A the presence of identical proteins in a 
Cy3- and Cy5-labelled sample results in a colour change to yellow as result of a green-
red overlay. 
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For the determination of the detection limit of CyDye-labelled protein, BSA was la-
belled with the Cy3- and Cy5-dye respectively. The labelled BSA was separated via 
SDS-PAGE, fixed and scanned in the corresponding channels with an ETTANTM DIGE 
scanner. The labelled BSA could be seen in the scanned picture at amounts up to 5 pg 
protein or 500 fmol (Fig. 22B). 
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Figure 22: (A): SDS-PAGE of Cy2- and Cy3-labelled proteins fished from a PMNL cell lysate (lane 
1 and 2) and a mixture of Cy2-and Cy3-labelled Cell lysates (line 3). (B) SDS-PAGE of CyDye-
labelled BSA. Data shown are representative of at least three independent experiments. 
 
4.1.5.8  IEF conditions for 2D-DIGE: 
 
For the separation in the first dimension, IPG-strips were chosen for isoelectric focus-
sing. The tray loading method combined with an active rehydration step resulted in the 
best performance for separating fishing eluates. 
First experiments with 7 cm IPG strips showed that only few proteins have a very high 
or a very low isoelectric point and that most of the protein spots are located in a more or 
less neutral pH range. Therefore IPG strips with a non-linear pH gradient between pH 3 
and pH 10 were used to achieve maximal separation in further experiments. 
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4.1.5.9 Development of the second dimension for 2D-DIGE 
 
Equilibration steps between IEF and second dimension separation via SDS-PAGE were 
optimised to ensure a sufficient protein transfer from IPG-strips to the polyacrylamide 
gel (conditions are shown in 3.2.6). separation in the second dimension was performed 
with a standard Tris-glycine SDS-PAGE system [25]. 
 
 
4.1.5.10 2D-DIGE result evaluation: 
 
2D-DIGE gels were digitised by scanning with an ETTANTM DIGE scanner (for in-
strument settings see 3.2.6.6). Differentially fished proteins were detected by compari-
son of both scanning channels in ImageQuantTM TL and DeCyderTM software. 
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4.2  Target-fishing experiments 
 
4.2.1 Acetaminophen (ACAP) 
 
Since the exact pharmacological mode of action of ACAP is still not clear, ACAP was 
chosen as ligand for target-fishing. Para-aminophenol conjugated with prolonged car-
bonic acid amides are known to be still pharmacological active [49]. Thus, N-glutaroyl-
aminophenol containing ACAP as substructure was chosen as ligand since the free, sec-
ond carboxylic acid allows specific linking to EAH Sepharose® 6B presumably keeping 
its pharmacological activity (Tab. 10). However, this fishing construct did not lead to 
the discovery of potential target candidates. Two additional constructs as well as corre-
sponding control constructs were generated. On the one hand, ACAP was coupled using 
its phenolic hydroxyl residue to epoxy-activated Sepharose® to receive a construct with 
an underivatised amide. Since the glutaroyl-ACAP showed poor solubility in common 
solvents, p-aminophenol was coupled to carboxy-activated methacylic acid beads. This 
immobilisation strategy offered two benefits: on the one hand the carboxy-activated 
matrix offers by far more functional groups than the EAH Sepharose®. On the other 
hand, p-aminophenol shows good solubility leading to a high immobilisation rate. An 
overview of the used ACAP fishing constructs is given in table 10. 
Nevertheless none of the used constructs led to fishing of potential target proteins. Sev-
eral cell lysates from PMNL, PBMC, platelets, Hela, Jurkat, PC12 and LNcap cells as 
well as different pre-clearing, washing and preparation methods of these lysates were 
tested without positive results. Also different separation methods like small (6 cm) and 
large (18 cm) scale 1D electrophoresis, 2D electrophoresis and 2D DIGE always led to 
identical spot patterns of immobilised ACAP and corresponding controls. 
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Figure 23: Identical protein-band pattern for proteins fishes with ACAP (immobilised on EAH-
Sepharose® 4B) and EAH-Sepharose® 4B without ligand. Fishing in PMNL cell lysate. See also Fig. 
17. 
 
To evaluate the functionality of the ACAP-mimicking N-glutaroyl-aminophenol fishing 
construct, fishing experiments in lysates of PBMC (COX-2) and of platelets (COX-1) 
were performed. Western blot analysis of the eluates shows that there is no higher affin-
ity for COX-1 or COX-2 to ACAP in comparison to the matrix control (Fig. 24). 
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Figure 24: COX-1 and COX-2 Western blot analysis of fishing eluates using an ACAP-mimicking 
fishing construct as ligand. 
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 Ligand Fishing construct 
A A´ N-glutaroyl-aminophenol 
(A) immobilised on amino 
activated beads (EAH 
Sepharose® 4B) (A´) and 
glutaric acid as control (B, 
B´) 
B 
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C C´ Acetaminophen (C) immo-
bilised on epoxy activated 
beads  ( Toyopearl AF-
Epoxy-650M) over the 
4´OH group (C´) and phe-
nol as control (D, D´) 
D D´ 
E E´ p-Aminophenol (E) immo-
bilised on carboxy activated 
beads (E´) and aniline as 
control (F, F´) 
F F´ 
Table 10: Immobilisation strategies for ACAP target-fishing: To obtain comprehensive fishing 
results for ACAP, the compound was immobilised in three different ways. First, N-glutaroyl-
aminophenol, containing ACAP as substructure was immobilised to EAH Sepharose® 4B (A, B). 
Second, ACAP itself was immobilised via its 4´-hydroxylic group (C, D) and p-aminophenol was 
immobilised to carboxy functionalised methacrylic acid beads as third construct (E,F). 
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4.2.2  Indirubin-3-monoxime (IR3MO) 
 
4.2.2.1 Immobilisation of IR3MO 
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Figure 25: Chemical structure of indirubin-3´-monoxime (A) and indole-3-carbinol (B) 
 
 
In contrast to indirubin, IR3MO possesses a monoxime moiety on the 3´-position that 
enhances its bioavailability (Fig. 25). Thus, the monoxime moiety does not affect the 
pharmacological properties of indirubin and can therefore be used for the immobilisa-
tion. Unfortunately, monoxime moieties are characterised by a very poor reactivity. 
Thus, no reactions are so far known to immobilise monoximes. However, Kurbanov et. 
al. showed in 1999 that ketoximes can be alkylated by reaction with α-epoxides [142]. 
Therefore, the immobilisation of IR3MO was performed using epoxy-activated beads ( 
Toyopearl AF-Epoxy-650M). For the immobilisation, IR3MO IV was solved in a 1:1 
(v/v) mixture of 5 N aqueous NaOH and acetone. The reaction took place at 60 °C for 
72 h under continual rotation. 
                                                 
IV
 IR3MO substance and VSMC lysates were kindly provided by the group of Prof. Dr. V. M. Dirsch, 
Department of Pharmacognosy, University of Vienna, Austria 
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Figure 26: Structure of fishing constructs for IR3MO (A) and I3C (B) as control. 
 
Indole-3-carbinol (I3C) was chosen as a substructure of IR3MO as negative control for 
IR3MO. Since I3C possesses a primary hydroxyl group, the immobilisation could be 
performed under standard conditions with epoxy activated beads (see 3.2.4.1.3) 
(Fig. 26). 
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4.2.2.2 Target-fishing experiments with IR3MO 
 
Since known anti-inflammatory and antitumoral effects of IR3MO were observed in 
vascular smooth muscle cells (VSMCs) by our cooperation partners IV (unpublished 
data), lysates of VSMCs as well as PMNL and PBMC lysates were used for fishing ex-
periments. Although there are visible spots in the DIGE experiments, protein amount of 
the fishing eluates were too low for detection by silver staining or subsequent MS ap-
proaches (Fig. 27). Additional experiments with cell lysates containing higher protein 
concentrations showed no significant improvement. 
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Figure 27: 2D-DIGE of indirubin-3-monoxime fished proteins from PBMC cell lysate. Red: Cy5 
labelled IR3MO fished proteins, green: Cy3 labelled indole-3-carbinole fished proteins. 
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4.2.3 Myrtucommulone A 
 
4.2.3.1 Immobilisation of Myrtucommulone A 
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Figure 28: Molecular structure of Myrtucommulone A 
 
For the immobilisation of Myrtucommulone V (MC) (Fig. 28), 10 mg MC were dis-
solved in 750 µl dioxane. After addition of an aqueous suspension of 140 mg 
Toyopearl® AF 650M Epoxy beads in 500 µl water, 10 µl of 10 N NaOH were added to 
adjust the pH value. Following steps were performed under standard conditions for ep-
oxy activated beads (see 3.2.4.1.3). 
 
 
4.2.3.2 Target-fishing experiments with Myrtucommulone 
 
DIGE analysis of a fishing experiment using PMNL lysate showed identical spot patters 
for MC and n-propanol blocked beads (Fig. 29). Hence, no protein selectively binding 
to MC could be identified. Propanol was used to block remaining reactive epoxy-
groups.  
 
                                                 
V
 Myrtucommulone was kindly provided by Prof. Dr. J. Jauch, Universität des Saarlandes, Organische 
Chemie II, Saarbruecken, Germany. 
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Figure 29: 2D-DIGE of proteins obtained from a fishing experiment using MC-Sepharose® and 
propranolol (control)-Sepharose® in lysates of PMNL. Red: Cy5 labelled MC fished proteins, 
green: Cy3 labelled control fished proteins, yellow: overlay of Cy5 and Cy3 labelled proteins. 
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4.2.4 Betulinic acid 
 
 
4.2.4.1  Immobilisation of betulinic acid 
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Figure 30: Molecular structure of betulinic acid (A) and lupeol (B) 
 
Betulinic acid (BA) possesses one single hydroxy residue and a carboxylic acid group 
as possible sites for linking to solid matrices (Fig. 30, 31). Given that the carboxylic 
group is supposed to be essential for the pharmacological action of BA, the hydroxy 
residue was chosen for the immobilisation of BA. Since there are no interfering func-
tional groups, BA could be immobilised without derivatisation steps directly to the 
Toyopearl® AF 650M Epoxy matrix. Knowing that the amount of a specifically bound 
protein varies in correlation to the amount of immobilised ligand (whereas unspecific 
bound proteins are always present in the same amount, independent from the amount of 
immobilised ligand), the binding specificity of a protein can be determined by compar-
ing bead batches with different ligand amounts. 
Thus, 1 µmol, 4 µmol and 40 µmol betulinic acid and 4 µmol lupeol (negative control) 
were dissolved in 100 µl THF respectively. This ligand solution was added to a suspen-
sion of 75 mg of epoxy-activated Toyopearl® AF 650M 500 µl THF. The coupling reac-
tion was started by addition of 100 µl of 1 M NaOH solution. Additional details of the 
coupling reaction are described in 3.2.4.1.3. 
 
64    4 Results 
O O
O
O
OH OH
OH
O
O O
O
O
OH OH
A
B
 
Figure 31: Structure of the BA and lupeol fishing constructs 
 
 
4.2.4.2  Fishing experiments with BA 
 
Fishing experiments with BA were performed in PMNL lysates in a semi-quantitative 
manner by relating eluates obtained from beads with different amounts of immobilised 
BA. Unspecific binding events resulted in bands with similar intensity independent of 
the amount of immobilised BA. Bands with increasing intensity at higher BA concentra-
tions indicate a selective binding to BA. A double band with a size of about 25 kDa was 
specifically detected in the BA samples and not in the lupeol control and showed an 
increasing binding pattern in correlation to the increasing amounts of immobilised BA 
(Fig. 32). The lower, stronger band was identified via MS analytics as cathepsin G (CG) 
whereas the higher but weaker band as proteinase 3 (PR3) (Tab. 11). 
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Figure 32: SDS-PAGE of proteins fished with a BA-affinity matrix from PMNL cell lysate and 
lupeol-matrix as control. Fishing was performed with beads coupled to different amounts of BA. 
Unspecific protein binding leads to bands with similar intensity (1) whereas the band intensity rises 
with higher amounts of immobilised BA for specific binding events (2). 
 
 Protein origin Sequence Score 
proteinase 3 (serine proteinase, neutrophil, 
Wegener granulomatosis autoantigen), isoform  
-.MASLQMR.G 40 
proteinase 3 (serine proteinase, neutrophil, 
Wegener granulomatosis autoantigen), isoform  
MASLQMR.G  
+Oxidation (M) 
(40) 
Spot 1 
proteinase 3 (serine proteinase, neutrophil, 
Wegener granulomatosis autoantigen), isoform  
R.LVNVVLGAHN
VR.T 
94 
Chain A, Human Cathepsin G R.QICVGDR.R 14 Spot 2 
Chain A, Human Cathepsin G R.NVNPVALPR.A 33 
Table 11: Mass spectrometric identification of proteins fished with a BA-affinity matrix: Mascot 
score significance level was 44, spot 1 was identified as proteinase 3 with a mascot score of 134, spot 
2 was identified as cathepsin G with a mascot score of 47. 
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4.2.4.3  Western blot confirmation 
 
Western blot analysis of the eluates confirmed the mass spectrometric results and 
showed the presence of both proteins, PR3 and CG in the eluates of BA-affinity matrix 
but not for proteins fished in lupeol-affinity matrix (Fig. 33). 
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Figure 33: (A): Silver staining of a SDS-PAGE performed with eluates of BA-fished proteins. Ar-
rows indicate spots that were cut out for protein analysis via MS. (B): Western blot experiment for 
PR3. Western blot data shown are representative of at least three independent experiments. 
 
 
4.2.4.4  CG and PR3 enzyme activity assay 
 
To investigate the functional effects of the interaction of BA with CG and PR3, enzyme 
activity assays for CG and PR3 were performed. In these enzyme assays, neither BA 
nor lupeol showed any functional effect on the enzymatic activity of CG (Fig. 34). For 
PR3, an inhibitory effect of BA was observed at concentrations ≥ 10 µM, whereas lu-
peol did not show a significant effect up to 30 µM (Fig. 35). 
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Figure 34: Activity assay for CG activity after BA and lupeol treatment. 
 
Proteinase 3 Inhibition by Betulinic Acid
0
20
40
60
80
100
120
DMSO BA 3 [µM] BA10 [µM] BA 30 [µM]
A
ct
iv
ity
 
[p
er
ce
n
ta
ge
 
o
f c
tr
l]
 
Figure 35: Activity of PR3 after treatment with BA. Data shown are representative of at least three 
independent experiments. 
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4.2.5 Resveratrol 
 
 
4.2.5.1  Derivatisation and immobilisation of Resveratrol 
 
Resveratrol possesses three phenolic hydroxylic residues. Each of them could be used 
for immobilisation but their similar pKs values and reactivities exclude a selective im-
mobilisation on only one of these three positions. Thus an appropriate derivative had to 
be synthesised. Since a derivatization on the 4´ position was found to not hinder RV 
activity on AKT phosphorylation (unpublished data), a carboxy-functionalised butyl 
linker was inserted at the C4 position (Fig.36B) VI. As negative control, phenoxybutyric 
acid (PBA) was immobilised to partially mimic the synthetic RV derivative (Fig.36C). 
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Figure 36: Resveratrol, B: carboxybutyl resveratrol for immobilisation, C: phenoxybutyric acid als 
control for 4´-O-carboxybutyl-resveratrol. 
 
For immobilisation of Resveratrol and PBA (Fig. 37), 16.7 mg Resveratrol and 9.58 mg 
PBA were dissolved in 1 ml dioxane. 200 µl Toyopearl® AF 650 Amino respectively 
were washed 2 times with 1 ml water, once with 1 ml dioxane 50% (v/v) and finally two 
times with 1 ml pure dioxane on a G4 glass filter crucible. The ligand solution, 10 µl 
1 N HCl and 20 µl DIC were added to the beads. The reaction was performed for 72 h at 
                                                 
VI
 Synthesis of the Resveratrol derivative (Fig. 36 B) was done by the group of Prof. Dr. T. Erker, 
Department of Medicinal Chemistry, University of Vienna, Austria 
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RT on a rotator. Subsequent washing steps were performed as described in 3.2.4 after 
completed reaction. 
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Figure 37: Immobilised resveratrol (A) and phenoxybutyric acid (B) as negative control 
 
 
4.2.5.2  Target-fishing experiments with RV 
 
Proteins were fished from PBMC lysates with resveratrol and PBA as negative control. 
After elution with 4 M urea, the released proteins were labelled with Cy3 and Cy5 dye, 
respectively (see 3.2.6.4). Proteins were separated via isoelectric focussing in the first 
dimension followed by SDS-PAGE in the second dimension. Spots were detected by 
scanning the gel with an ETTANTM DIGE imager with a resolution of 100 µm and an 
exposure time of 2 sec (Fig. 38). 
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Figure 38: 2D-DIGE of resveratrol-fished proteins from PBMC lysates. Red: Cy5 labelled proteins 
fished by resveratrol, green: Cy3 labelled proteins fished by PBA, yellow: overlay of Cy5 and Cy3 
labelled proteins. Marked spots were picked for identification via MS analytics. 
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The gel image was analysed with DeCyderTM 7 software to selectively detect RV-fished 
proteins (Fig. 39). 
 
 
Figure 39: Evaluation of the protein distribution of RV fished proteins. 7473 spots could be de-
tected on the gel. 454 spots were excluded due to their high slope indicating artificial spots (colour-
less). 4087 spots were detected in the same amount in the RV fishing eluate and the control eluate 
(yellow). 1589 spots were detected as selectively fished with RV (red) and 1343 proteins were pre-
sent in the control but not in the RV sample (green). 
 
 
For picking differentially fished proteins, the proteins were visualised by silver staining. 
In the DIGE gel, the differential pattern of selectively fished proteins showed protein 
sets with the same size differing in their IEP. Since this indicates that these sets consist 
of the same protein but different ionic forms (e.g., due to differential phosphorylation), 
only one spot out of each set was picked for MS analysis. 
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Figure 40: Intensity profile of the DIGE experiment with PBMC cell lysate. Indicated spots are 
marked with an arrow. 
 
The fluorometric comparison of RV- and PBA-fished proteins from the DIGE gel 
clearly showed a higher presence of proteins fished by RV at spot number 2, 5 and 6 as 
compared to respective proteins fished by PBA (Fig. 40). 
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 Resveratrol fished PBA (control) fished 
Spot 2 
Volume ratio: 
1226% 
 
RV. Vol.: 132843 
Ctrl. Vol.: 7695 
 
Spot 5 
Volume ratio: 
366% 
 
RV. Vol.: 49067 
Ctrl. Vol.: 9534 
 
Spot 6 
Volume ratio: 
1459% 
 
RV. Vol.: 149962 
Ctrl. Vol.: 7301 
 
Table 12: 3D single spot evaluation and spot volume calculation of the DIGE experiment. 
 
Exact determination of the spot volumes show that the protein at the analysed spots are 
present in a RV/control volume ration of 1226 in spot 2, 366 in spot 5 and 1459 in spot 
6. The 3 dimensional visualisation of the spot volume clearly shows the presence of 
these proteins in the RV fishing as well as the absence in the appropriate negative con-
trol (Tab. 12). 
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 Protein origin Sequence Score 
KHSRP KH-type splicing regulatory protein IINDLLQSLR 63 
KHSRP KH-type splicing regulatory protein AWEEYYK 46 
KHSRP KH-type splicing regulatory protein IGGGIDVPVPR 45 
FUBP1 Isoform 1 of Far upstream element-
binding protein 1 
IGGNEGIDVPIPR 67 
FUBP1 Isoform 1 of Far upstream element-
binding protein 1 
IQIAPDSGGLPER 68 
FUBP1 Isoform 1 of Far upstream element-
binding protein 1 
LLDQIVEK 55 
FUBP1 Isoform 1 of Far upstream element-
binding protein 1 
GTPQQIDYAR 46 
Spot 2 
FUBP1 Isoform 1 of Far upstream element-
binding protein 1 
IAQITGPPDR 44 
KHSRP KH-type splicing regulatory protein IGGGIDVPVPR 71 
KHSRP KH-type splicing regulatory protein IIGDPYK 55 
KHSRP KH-type splicing regulatory protein IINDLLQSLR 58 
KHSRP KH-type splicing regulatory protein VQISPDSGGLPER 65 
KHSRP KH-type splicing regulatory protein AWEEYYK 43 
Spot 5 
KHSRP KH-type splicing regulatory protein DAFADAVQR 47 
KHSRP KH-type splicing regulatory protein IGGGIDVPVPR 71 
KHSRP KH-type splicing regulatory protein IINDLLQSLR 68 
KHSRP KH-type splicing regulatory protein MMLDDIVSR 61 
KHSRP KH-type splicing regulatory protein VQISPDSGGLPER 63 
Spot 6 
KHSRP KH-type splicing regulatory protein DAFADAVQR 47 
Table 13: Peptides detected via MS analytics and corresponding mascot search results 
 
For all three spots the KH-type splicing regulatory protein (KHSRP) was identified via 
mass spectroscopy (Tab. 13). 
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4.2.5.3 Western blot confirmation 
 
The fishing experiment was repeated under the same conditions as for the DIGE gel 
analysis to confirm the MS results by immunological methods. Thus, a Western blot 
analysis was performed with the fishing eluates of RV and the corresponding PBA con-
trol. 
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Figure 41: Western blot analysis of KHSRP in eluates from RV-fished proteins, PBA-fished pro-
teins and the matrix-fished proteins. Data shown are representative of at least three independent 
experiments. 
 
The detection of KHSRP by Western blot analysis clearly shows the presence of 
KHSRP in the fishing eluate of the RV fishing construct, but neither in eluates of the 
PBA construct nor the matrix itself (Fig. 41). 
 
4.2.6 Testosterone / Progesterone 
 
4.2.6.1 Immobilisation of Testosterone and Progesterone 
 
For a successful immobilisation, testosterone and progesterone had to be derivatised. 
Altogether, three different derivatives were synthesisedVII and subsequently immobi-
lised. These derivatives are: i) progesterone and testosterone with a carboxymethoxyl-
amine function on the C3 position; ii) progesterone and testosterone with a pentanoic 
acid function on the C7 position; iii) testosterone derivative with a hydroxyl activated 
polyethylenglycol linker on the C17 position (see Fig. 43). 
 
 
                                                 
VII
 Synthesis of all steroid derivatives was done in cooperation by dipl. chem. M. Golkowski and the 
group of Prof. Dr. T. Ziegler, Institute of Organic Chemistry, University Tübingen 
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4.2.6.2 Immobilisation of the C3 derivatised testosterone and progesterone 
 
2 × 3.3 ml Toyopearl® AF 650M Amino were washed as described in 3.2.4. 375 mg 
progesterone carboxymethoxylamine and 360 mg testosterone carboxymethoxylamine 
were dissolved in 2 ml dioxane. After addition of 350 µl DIC and 10 µl HCl (1 N) the 
reaction was performed for 72 h at RT on a rotator. After the reaction was completed, 
washing steps were performed according to 3.2.4. 
Carboxymethoxylamin derivatised testosterone and progesterone were coupled to EAH 
Sepharose® 4B under the same conditions using only a tenth of ligand as for immobili-
sation on Toyopearl® AF 650M Amino. 
 
4.2.6.3 Immobilisation of the C17 derivatised testosterone and progesterone 
 
The testosterone and progesterone derivatives with a hydroxyl-activated poly-
ethylenglycol linker on C7 were immobilised on Epoxy-activated Sepharose® 6B beads 
using standard conditions (see 3.2.4.1.3). 
 
4.2.6.4 C7 derivatised testosterone and progesterone 
 
The testosterone and progesterone derivatives with a pentanoic acid function on C7 
were immobilised on Toyopearl® AF 650M Amino beads using standard conditions (see 
3.2.4). 
 
Steroids with a partially unsaturated A-ring show fluorescence at 366 nm after treatment 
with ethanolic sulfuric acid which was used to detect successful immobilisation of ster-
oid derivatives
 
(see Fig. 42). 
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Figure 42: Fluorescence analytics of immobilised testosterone derivatives 
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Figure 43: Testosterone (A), progesterone (B) and their derivatised forms used for immobilisation: 
testosterone carboxymethoxylamin (C), progesterone carboxymethoxylamine (D), C7 pentanoic 
acid testosterone (E), C7 pentanoic acid progesterone (F) and C17 ethinyl-polyglycol derivatised 
testosterone. 
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4.2.6.5 Target-fishing in PMNL cell lysates using C3- and C17-derivatised testos-
terone 
 
The fishing experiment was performed as described in chapter 3.2 using PMNL cell 
lysate as protein source. To avoid problems regarding different protein amounts due to 
experimental inaccuracies, the fishing experiment with testosterone beads was per-
formed with only 60% and 30% of the protein concentration of the control samples. 
Since these experimental inaccuracies are by far smaller than 30% or 60%, differences 
in the band intensity are caused by different affinities to the ligands.  
The samples were eluted with SDS buffer (see 3.2.5.3) and separated via SDS-PAGE. 
Detection by silver staining showed one band with 69 kDa and one with approximately 
95 kDa, both present in the eluate of C3-testosterone but missing in both, the C17 and 
the EAH-Sepharose® eluates. Since these bands were visible also in eluates from fishing 
approaches conducted only with 60% and 30% protein amount, they were a clear result 
for proteins with a higher affinity to C3 testosterone than to C17 testosterone (Fig. 44). 
Indicated bands were picked out and analysed by MS as described (3.2.6.6). 
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Figure 44: (A) SDS-PAGE of proteins fished with C3- and C17-derivatised testosterone in PMNL 
cell lysates visualised by silver staining. (B): SDS-PAGE of carboxymethoxylamine fished proteins 
from PMNL cell lysates visualised via silver staining 
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Protein name Serum albumin 
[homo sapiens] 
Karyopherin beta 1 
[homo sapiens] 
MW [kDa] 69.3 97.1 
Sequence coverage [%] 19 5 
Mascot score 670 165 
No. of matched peptides 15 5 
Significance threshold mascot score >39 
Table 14: Peptide sequences derived from the indicated spots after tryptic digest and MS analytics 
and corresponding mascot search results 
 
The sequenced protein at 69 kDa was identified as human serum albumin (Tab. 14). 
Since this is a protein that is known to bind steroids [143], it implies that the testoster-
one derivative immobilised via C3 exhibits the structural properties required for binding 
to/fishing of known interacting proteins. Instead, it was not possible to fish a known 
interacting protein with the testosterone derivative linked on C17, indicating that this 
derivative might not exhibit the biochemical functionality of testosterone. 
 
The 95 kDa protein was identified as karyopherin β (KPN-β) (Tab. 14) by MS analytics. 
Since this protein is an interesting target candidate, Western blot analysis using a KPN-
β antibody was performed to validate the results of the MS analytics. In addition to the 
upper experiment immobilised progesterone was used as control. 
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Figure 45: KPN-β Western blot analysis of testosterone (C3 TD) and progesterone (C3 PD) fished 
proteins. Data shown are representative of at least three independent experiments. 
 
In contrast to the SDS-PAGE developed with silver staining, Western blot analysis of 
the fishing eluates showed same intensities of the bands for testosterone and the matrix 
without any derivatisation (Fig. 45). In addition, in a sample of progesterone-fished pro-
teins, where progesterone was immobilised in the same way as testosterone, the same 
intensity of the KPN-β band was detected. Since KPN-β turned out to bind to the Sepha-
 4 Results   81 
rose® surface itself, a selective testosterone-KPN-β interaction could not be confirmed 
and is conseqently excluded. 
 
 
4.2.6.6 2D-DIGE analysis of testosterone and progesterone fished proteins 
 
Fishing experiments for subsequent DIGE analysis were performed with C3-derivatised 
testosterone and progesterone coupled to Toyopearl® AF 650M Amino. For comprehen-
sive fishing results, the fishing- and DIGE experiments were performed separately with 
lysates of PMNL, PBMC and platelets. 
 
 
4.2.6.7 Testosterone and progesterone fishing in PMNL cell lysates 
 
Fishing experiments were performed as described in 3.2.5. Proteins were eluted using 4 
M urea and subsequently labelled with appropriate fluorophoric groups (CyDyeTM-fluor 
labelling, see 3.2.6). 2D electrophoresis was performed and proteins on the 2D gel were 
visualised by scanning the gel with the ETTANTM DIGE scanner (see 3.2.6) (Fig. 46). 
The spot pattern of the gel was evaluated using the ImageQuantTM TL software to iden-
tify differentially fished proteins. Detailed evaluation of the differentially fished protein 
spots was executed with the DeCyderTM software. 
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Figure 46: 2D-DIGE of testosterone and progesterone fished proteins from PMNL cell lysate. Red: 
Cy5 labelled proteins fished by testosterone, green: Cy3 labelled proteins fished by progesterone, 
yellow: overlay of Cy5 and Cy3 labelled proteins. Marked spots showed a prominent difference of 
protein amount in the compared samples. 
 
The 39 spots with the most prominent difference between the testosterone and proges-
terone sample were analysed in detail (Fig. 48, 49). Due to the fact that the detection via 
CyDyeTM labelling is up to 500 fold more sensitive than silver staining, only 18 of these 
39 spots could be recovered in the silver stained 2D gel. Since spots that are not visible 
after a silver staining can not be picked for MS analytics, spot selection and evaluation 
focussed on the 18 spots that were visualised by silver staining (Fig. 47). 
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Figure 47: Silver staining of the 2D-DIGE gel of figure 46; testosterone and progesterone fished 
proteins from PMNL cell lysate. Marked spots were picked for identification via MS analytics. 
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Figure 48: Spot distribution histogram of the testosterone DIGE experiment with PMNL cells. 4767 
spots were detected on the gel whereas 576 spots (colourless) were recognised as artificial spots due 
to their high slope and therefore are not included in following calculation steps. From the remain-
ing 4191 spots 3245 (77.4%) spots were recognised to show no differences within a threshold of 
200% (yellow). 455 (10.9%) spots were recognised to be present in at least two fold amount in the 
progesterone eluate (green) whereas 491 (11.7%) spots showed this in the testosterone sample (red). 
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Figure 49: Intensity profile of the DIGE experiment in PMNL. Green profile: Cy3 labelled, proges-
terone fished proteins. Red profile: Cy5 labelled, testosterone fished proteins. Indicated spots are 
marked with a vertical green line. 
 
For detailed quantitative analytics of the single spots, the peak volumes as well as the 
volume ratio of corresponding spots were calculated (Tab. 15). 
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Spot values Testosterone fished Progesterone fished 
Spot No.1: 
Volume ratio: 
102% 
Test. Vol.: 2365867 
Prog. Vol.: 3217799 
 
Spot No.8: 
Volume ratio: 
338% 
Test. Vol.: 636806 
Prog. Vol.: 2881478 
 
Spot No.14: 
Volume ratio: 
241% 
Test. Vol.: 579498 
Prog. Vol.: 187057 
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 Testosterone fished Progesterone fished 
Spot No.18: 
 
Volume ratio: 
324% 
Test. Vol.: 312803 
Prog. Vol.: 1356441 
 
Spot No.20: 
Volume ratio: 
655% 
Test. Vol.: 601186 
Prog. Vol.: 122700 
 
Spot No.39: 
Volume ratio: 
264% 
Test. Vol.: 437713 
Prog. Vol.: 1547362 
 
Table 15: 3D single spot evaluation and spot volume calculation of the DIGE experiment. 
 
MS analytics of the indicated spots and following mascot evaluation of the measured 
peptides led to following results (Tab. 16). 
Vimentin was identified in spot 1 with a low mascot score and in spot 8 and 10 with 
high mascot scores. Serpin B1 was identified for spots14 and 18, HSP B1 for spot 20 
and NAMPT for spot 39. The remaining spots had low scores or contradictory results 
for single peptide sequences. Spots detected as keratin were not considered since the 
protein amount was to low to detect the actual protein besides keratin contaminations. 
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 Protein origin sequence score 
VIM Vimentin FADLSEAANR 54 
VIM Vimentin QDVDNASLAR 48 
ACTB Actin, cytoplasmic 1 DLTDYLMK 46 
ACTB Actin, cytoplasmic 1 DSYVGDEAQSK 61 
ACTB Actin, cytoplasmic 1 GYSFTTTAER 46 
PML Isoform PML-1 of Probable transcription 
factor PML CDISAEIQQR 48 
PML Isoform PML-1 of Probable transcription 
factor PML TGSALVQR 52 
Spot 1 
PML Isoform PML-1 of Probable transcription 
factor PML LDAVLQR 41 
VIM Vimentin QDVDNASLAR 85 
VIM Vimentin QVDQLTNDK 57 
VIM Vimentin FADLSEAANR 40 
Spot 8 
VIM Vimentin QQYESVAAK 37 
VIM Vimentin FADLSEAANR 54 
VIM Vimentin QDVDNASLAR 68 
VIM Vimentin QQYESVAAK 40 
Spot 
10 
VIM Vimentin QVDQLTNDK 38 
SERPINB1 Leukocyte elastase inhibitor IEEQLTLEK 66 
SERPINB1 Leukocyte elastase inhibitor LGVQDLFNSSK 46 
SERPINB1 Leukocyte elastase inhibitor ADLSGMSGAR 41 
SERPINB1 Leukocyte elastase inhibitor KIEEQLTLEK 43 
Spot 
14 
SERPINB1 Leukocyte elastase inhibitor TINQWVK 35 
SERPINB1 Leukocyte elastase inhibitor FQSLNADINK 48 
SERPINB1 Leukocyte elastase inhibitor IEEQLTLEK 62 
SERPINB1 Leukocyte elastase inhibitor KIEEQLTLEK 75 
SERPINB1 Leukocyte elastase inhibitor LGVQDLFNSSK 47 
Spot 
18 
SERPINB1 Leukocyte elastase inhibitor ADLSGMSGAR 36 
HSPB1 Heat shock protein beta-1 AQLGGPEAAK 57 
HSPB1 Heat shock protein beta-1 DGVVEITGK 47 
HSPB1 Heat shock protein beta-1 QDEHGYISR 60 
HSPB1 Heat shock protein beta-1 QLSSGVSEIR 59 
Spot 
20 
HSPB1 Heat shock protein beta-1 TKDGVVEITGK 70 
NAMPT Isoform 1 of Nicotinamide phospho-
ribosyltransferase DLLNCSFK 46 
NAMPT Isoform 1 of Nicotinamide phospho-
ribosyltransferase KFPVTENSK 56 
NAMPT Isoform 1 of Nicotinamide phospho-
ribosyltransferase TPAGNFVTLEEGK 69 
NAMPT Isoform 1 of Nicotinamide phospho-
ribosyltransferase NAQLNIELEAAHH 39 
Spot 
39 
NAMPT Isoform 1 of Nicotinamide phospho-
ribosyltransferase SYSFDEIR 39 
Table 16: Peptide sequences derived from the indicated spots after tryptic digest and MS analytics 
and corresponding mascot search results. 
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Spots that are not described in table 16 either (i) could not be referred to a certain pro-
tein with an adequate score value, (ii) resulted in a identification of a unknown or hypo-
thetical protein or (iii) were identified as keratin or actin which are known to be possible 
contaminations in 2D-DIGE or MS approaches.  
 
4.2.6.8 Testosterone and progesterone fishing in PBMC cell lysates 
 
Fishing experiments and 2D-DIGE analysis were performed as described above (3.2.5 
and 3.2.6) using PBMC cell lysate as protein source. The high concentration of actin on 
a 2D-gel analysed by ETTANTM DIGE led to a smeary band at 45 kDa (Fig. 58). This 
high actin concentration caused an insufficient focussing in the first dimension and poor 
resolution of proteins with a higher molecular weight than actin in the second dimen-
sion. Thus, no clearly separated spots could be seen in the upper part of the gel. The 
poor resolution in combination with the lower sensitivity of the subsequent silver stain-
ing finally resulted in only five differentially fished spots with suitable protein amounts 
for subsequent MS analytics (Tbl. 20, Fig. 59, 60). 
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Figure 50: 2D-DIGE of proteins fished with testosterone and progesterone in PBMC cell lysates. 
Green: Cy5 labelled testosterone fished proteins, red: Cy3 labelled progesterone fished proteins, 
yellow: overlay of Cy3 and Cy5 labelled proteins. Marked spots were picked for identifikation via 
MS analytics. 
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Figure 51: Spot distribution of the DIGE experiment with testosterone and progesterone in PBMC 
cell lysate. Evaluation via the DeCyder7 algorithm showed a total number of 6072 spots. 1129 spots 
were excluded since a high slope indicated an artificial origin (excluded spots are not shown). From 
the remaining 4943 spots 3609 were recognised with similar intensities in both, the testosterone and 
progesterone, fishing eluates (yellow). Finally, 360 spots were detected with higher intensity for 
progesterone (green) and 974 spots with a higher presence in the testosterone sample (red). 
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 Testosterone fished Progesterone fished 
Spot 10 
Volume ratio: 
231% 
 
Test. Vol.: 196016 
Prog. Vol.: 597040 
 
Spot 13 
Volume ratio: 
310% 
 
Test. Vol.: 182794 
Prog. Vol.: 746862 
 
Spot 15 
Volume ratio: 
252% 
 
Test. Vol.: 301130 
Prog. Vol.: 999260 
 
Table 17: 3D single spot evaluation and spot volume calculation of the DIGE experiment. 
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Figure 52: Intensity profile of the DIGE experiment in PBMC. Green profile: Cy3 labelled, proges-
terone fished proteins. Red profile: Cy5 labelled, testosterone fished proteins. Indicated spots are 
marked with a green line. 
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Table 18: Peptide sequences derived from the indicated spots after tryptic digest and MS analytics 
and corresponding mascot search results. 
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The spots number 6 and 13 were both identified as Heat shock protein beta-1 (= Heat 
shock protein 27). For spot number 15, peptides of Heat shock protein beta-1 as well as 
of Peroxiredoxin-6 were identified. 
 
Spot 10 was identified as isoform 1 of Abhydrolase domain-containing protein 14B 
(ABHD14B) which is not known in literature. Thus, subsequent validation and charac-
terisation of ABHD14B is not possible and ABHD14B was not considered further on 
(Tbl. 21). 
 
 
4.2.6.9 Testosterone and progesterone fishing in platelet lysates 
 
For target-fishing in platelet cell lysates, experiments were performed as described in 
3.2.5. 2D DIGE was performed under standard conditions as described in 3.2.6[144-
148]. However, only two spots could be picked out of the silver stained gel for subse-
quent MS analytics (Fig. 61). Interestingly, both spots were identified as HSP B1 al-
though they were clearly separated. 
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Figure 53: 2D-DIGE of proteins fished with testosterone and progesterone in platelet cell lysates. 
red: Cy5 labelled testosterone fished proteins, green: Cy3 labelled progesterone fished proteins, 
yellow: overlay of Cy3 and Cy5 labelled proteins. Marked spots were picked for identification via 
MS analytics. 
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Figure 54: Spot distribution of the DIGE experiment with testosterone and progesterone in platelet 
cell lysate. DeCyder analysis detected 5068 spots including 335 spots with artificial origin (colour-
less). Non artificial spots consisted of 3851 spots with no difference (yellow), 338 spots of proteins 
fished selectively with progesterone (green) and 544 spots of proteins with a higher amount in the 
testosterone eluates (red). 
 
 Testosterone fished Progesterone fished 
Spot 2 
Volume ratio: 
659% 
 
Test. Vol.: 1082553 
Prog. Vol.: 5047068 
 
Spot 1 
Volume ratio: 
179% 
 
Test. Vol.: 3700332 
Prog. Vol.: 1465368 
 
Table 19: 3D single spot evaluation and spot volume calculation of the DIGE experiment. 
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Figure 55: Intensity profile of the DIGE experiment in platelet cell lysate. Green profile: Cy3 la-
belled, progesterone fished proteins. Red profile: Cy5 labelled, testosterone fished proteins. Indi-
cated spots are marked with a green line. 
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Table 20: Peptide sequences derived from the indicated spots after tryptic digest and MS analytics 
and corresponding mascot search results 
 
Both, the protein contained in spot 1 and 2 were identified as Heat shock protein beta 1 
(HSP B1) (Fig. 62, 63; Tab. 22, 23). 
 
4.2.6.10  Confirmation via Western blot analysis 
 
Western blot analysis of fishing eluates was performed in order to confirm the results of 
the MS analytics (Fig. 64). 
 4 Results   99 
PBMC PMNL
Vimentin
Visfatin
Serp B1
Te
st.
Pr
og
.
M
atr
ix
Te
st.
Pr
og
.
M
atr
ix
 
Figure 56: Western blot analysis of proteins fished with testosterone and progesterone in PMNL 
and PBMC cell lysates. Data shown are representative of at least three independent experiments. 
 
Next, Western blot analysis was performed with eluates obtained from fishing experi-
ments with PMNL and PBMC cell lysates. Vimentin (Vim) could be fished selectively 
with progesterone in PBMC cell lysates. In eluates from fishing experiments in PMNL 
cell lysates, only a slight difference with more Vim in the fishing experiment using pro-
gesterone as bait could be seen. For visfatin (Vis) a clear band could be identified in the 
testosterone fishing experiments in PBMC cell lysates, whereas no band was visible in 
the corresponding progesterone sample. For Vis blots from the PMNL lysate fishing, a 
stronger band for testosterone eluates than for progesterone eluates was detected. Re-
garding Serpin B1, Western blot analysis results from the fishing experiments in both, 
PBMC and PMNL cell lysates showed no clear difference between testosterone and 
progesterone. For all Western blots the matrix alone turned out to bind no or very low of 
the analysed protein. 
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4.2.6.11 Evaluation of Vimentin as target structure 
 
The protein Vimentin (Vim) is an intermediate filament and thereby part of the cy-
toskeleton. Although scientists recognised that Vim is not a classical part of the cy-
toskeleton but a regulatory protein (see [144-147]) its function is only poorly under-
stood and no assay systems for testing regulatory effects of Vim exist so far. Thus, no 
further experiments could be performed to characterise the functionality of the proges-
terone – Vim interaction. 
 
 
4.2.6.12 Evaluation of Serpin B1 as target structure 
 
Since the specificity of the Serpin B1 – progesterone interaction could not be confirmed 
in Western blot experiments, no further experiments were performed to validate the 
Serpin B1 – progesterone interaction. 
 
 
4.2.6.13 Evaluation of HSP27 as target structure 
 
In PBMC and PMNL, HSP27 binds to both: testosterone and progesterone with a 
slightly higher affinity to testosterone. In contrast, fishing experiments performed in 
platelets resulted in a prominent band in the Western blot experiment for HSP27 for the 
testosterone sample, whereas almost no band was visible for the progesterone sample 
(Fig. 65). 
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Figure 57: (A) Western blot analysis of HSP27 fished by testosterone and progesterone in PBMC-, 
PMNL- and platelet lysates. (B) Western blot analysis of HSP27 and p(Ser82)HSP27 fished by tes-
tosterone and progesterone in platelet lysates. Data shown are representative of at least three inde-
pendent experiments. 
 
To determine whether the binding of HSP27 to testosterone is a direct interaction or 
mediated via adaptor proteins a fishing experiment with isolated recombinant HSP27 
was performed. Western blot analysis showed that only testosterone but not progester-
one is able to bind isolated HSP27 and thereby causes a reduction of the protein in the 
supernatant (Fig. 66). 
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Figure 58: Western blot analysis of a testosterone fishing with isolated recombinant HSP27 and its 
supernatant. Data shown are representative of at least three independent experiments. 
 
In the DIGE experiment performed with platelet lysates, two separated spots (one fished 
with testosterone and one with progesterone) were both identified as HSP27 (see Fig. 
61). The result of the Western blot analysis might explain the second spot correspond-
ing to HSP27 in the testosterone sample. In contrast, progesterone was able to pull 
down HSP27 in the DIGE experiment but not in the Western blot analysis. Since both 
spots of HSP27 differed in their isoelectric point but not in their size, we considered that 
different phosphorylation states could differentially influence the binding affinity to 
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progesterone. In fact, protein phosphorylation may cause a shift of the isoelectric point. 
Thus, further Western blot analysis with antibodies against p(Ser82)HSP27 were per-
formed (Fig. 65B). These results showed that the phosphorylated HSP27 binds clearly 
to progesterone, whereas unphosphorylated HSP27 does barely bind to progesterone. 
 
The levels of HSP27 and pHSP27 in platelets from male and female donors were ana-
lysed by Western blot analysis. The levels of both HSP27 and pHSP27 were distinctly 
higher in platelets from female donors compared with platelets from male donors. 
Knowing that the binding affinity of progesterone to HSP27 is lower than to testoster-
one, these results suggest that the levels of HSP27 in platelets from female donors com-
pensates the lower binding affinity of HSP27  to progesterone (Fig. 67). 
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Figure 59: (A): Western blot analysis of HSP27 and p(Ser82)HSP27 fished in platelets; (B): West-
ern blot analysis of the HSP27 and p(Ser82)HSP27 amount in platelets from male- and female do-
nors and Actin as loading control. Data shown are representative of at least three independent ex-
periments. 
 
 
4.2.6.14 Evaluation of visfatin as target structure 
 
To investigate whether the visfatin (Vis) interacts directly or via an adaptor protein to 
testosterone, fishing experiments with isolated Vis were performed. In the Western blot 
analysis of this fishing experiment, a specific interaction between testosterone and Vis 
was seen. In addition, a decrease of the Vis amount in the supernatant indicated that Vis 
can be selectively fished out of solution (Fig. 68). 
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Figure 60: Western blot analysis of a testosterone fishing with isolated recombinant visfatin. After 
the fishing experiment visfatin levels are decreased in the supernatant (sn ctrl.) of the testosterone 
fishing, whereas elution of the beads (fishing) shows the presence of visfatin specifically in the tes-
tosterone sample. Data shown are representative of at least three independent experiments. 
 
Since both, testosterone and Vis are known to influence ERK phosphorylation [96, 
149], experiments on combined effects of both compounds have been performed as de-
scribed in 3.2.7.1 (Fig. 69). 
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Figure 61: Western blot analysis of the ERK phosphorylation assay. DMSO was used as vehicle 
control. Monocytes (Mono) and neutrophils (PMNL) were incubated 90 sec with DHT (30 nM), 
Visfatin (100 nM) or fMLP (100 nM). Data shown are representative of at least three independent 
experiments. 
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Figure 62: Western blot analysis of the AKT phosphorylation assay. DMSO was used as vehicle 
control. Monocytes (Mono) were incubated 90 sec with DHT (30 nM), Visfatin (100 nM) or fMLP 
100 nM. Data shown are representative of at least three independent experiments. 
 
DHT enhances the basal phosphorylation state of ERK as well as Vis. The combination 
of DHT and Vis resulted in the highest phosphorylation state of ERK. These effects 
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could be shown in monocytes and PMNL. No difference of the effects between genders 
could be observed. Although it has been described, that AKT can, like ERK, be phos-
phorylated by addition of Vis [149-150], this effect was not observed in our experi-
ments (Fig. 70). 
 
4.2.6.15 Comparison of different testosterone and progesterone derivatives 
 
Since the possibilities to immobilise a compound is limited to its chemical structure, 
derivatives have to be synthesised to obtain new possibilities for successful target-
fishing experiments. Thus, in the course of this study, several derivatives have been 
synthesised by collaboratorsVIII. To find out which derivatives of a certain compound 
are most convenient for target-fishing experiments, multiplexed DIGE experiments 
were performed. 
To compare C3 carboxymethoxylamine derivatives of testosterone and progesterone 
with corresponding C7 pentanoic acid derivatives, fishing experiments were performed 
with both derivatives as well as with the uncoupled matrix. Both progesterone deriva-
tive eluates were labelled with the Cy3 dye whereas both testosterone eluates were Cy5 
labelled. In addition, a sample consisting of an aliquot of each eluate was labelled with 
the Cy2 dye. Thus, two corresponding testosterone and progesterone eluates as well as 
the Cy2 labelled sample could be separated on one 2D gel. The Cy2 labelled sample as 
internal standard allows the comparison of different 2D DIGE gels with the same inter-
nal standard (Fig. 73). 
 
                                                 
VIII
 Synthesis of all steroid derivatives was done in cooperation by dipl. chem. M. Golkowski and the 
group of Prof. Dr. T. Ziegler, Institute of Organic Chemistry, University Tübingen 
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Figure 63: Scheme of the multiplexed DIGE experiment. Samples were labelled with Cy3 or Cy5 
dyes respectively. A mixture of all 6 samples was labelled with the Cy2 dye to obtain a multiplexed 
standard. 3 different gels were loaded with a Cy3 labelled and a Cy5 labbelded sample as well as 
with the Cy2 labelled standard. 
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Figure 64: Comparison of proteins fished by differentially immobilised steroid. Blue: artificial 
spots, yellow spots: proteins with no difference in their affinity for progesterone and testosterone, 
red spots: proteins fished with a higher selectivity for testosterone, green spots: proteins fished with 
a higher selectivity for progesterone. 
 
The entire evaluation of fished proteins showed that more proteins are fished with the 
C7 derivatives of testosterone and progesterone in comparison to the C3 derivatives. 
The fishing experiment with C3 derivatives led to the detection of 1472 spots whereas 
3937 spots could be detected in the eluates of the C7 derivative fishing experiment. In 
addition, fishing with C7 derivatives led to less unspecific fished proteins. While 80.7% 
of all spots in the C3 fishing eluates were detected with similar concentrations for pro-
gesterone and testosterone only 72.0% of the proteins in the C7 derivative eluates were 
present in similar amounts (Fig. 74). 
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5 Discussion 
 
State of the art pharmacotherapy requires a comprehensive understanding of the mo-
lecular action of a drug. Therefore, durg-target research is one of the major disciplines 
of modern medical and pharmaceutical science. 
As mentioned above, today´s drug-target research focusses on the development of new 
drugs for known targets. In addition, the effectiveness of many natural compounds that 
were traditionally used for the treatment of several diseases is rediscovered by today´s 
medical scientists. These findings are often limited to clinical observations and the mo-
lecular base for the effects of these compounds often remains unclear. Thus, the identi-
fication of new targets for known compounds offers an important possibility of a ra-
tional pharmacotherapy for compounds that are known to be effective and safe in use 
for a long time. 
Up to date, there is a lack of knowledge for molecular drug actions as well as a lack of 
suitable methods for the investigation of these drug actions. 
 
 
5.1 Methodological improvements of the target-fishing approach 
 
The target-fishing approach was successfully used in the past for the identification of 
new targets for known compounds [18-19]. Although the results of Harding et. al. and 
Taunton et. al. impressively showed the potency of the target-fishing approach it was 
barely regarded by scientists and no efforts were made to improve the target-fishing 
approach. Comprehensive investigations on matrix types, fishing and elution conditions 
as well as the establishment of modern proteomic methods are needed to develop the 
target-fishing approach to a reliable and versatile method. 
 
5.1.1 Matrix types for target-fishing experiments 
 
The chemical composition of a fishing-matrix plays an essential role for the success of 
target-fishing experiments. It has to provide an appropriate type and amount of func-
tional groups, it has to possess sufficient chemical resistance and it should show low 
unspecific protein interaction. 
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As mentioned in 4.1.1, matrices consisting of polymethacrylic acid turned out to possess 
extended chemical resistance and thereby offer a wide range of possibilities for subse-
quent chemical modifications. In addition, matrices based on methacrylic acid are avail-
able with a distinct higher immobilisation capacity. Amino functionalised methacrylic 
matrices such as Toyopearl AF Amino-650M, for example, possess tenfold higher 
amounts of functional groups compared to the commonly used EAH Sepharose® 4B. 
Thus, methacrylic acid matrices combine both the possibility to immobilise a higher 
amount of ligand and more options of chemical reactions to immobilise ligands. 
 
 
5.1.2 Generation of carboxymethoxylamine beads for immobilisation of ligands 
via keto- or aldehyde groups 
 
Carboxymethoxylamine residue allows the immobilisation of both ketones and alde-
hydes under mild reaction conditions, which are both compatible with beads and harm-
less to a wide range of possible ligands. Up to date, carboxymethoxylamine activated 
beads are neither commercial available, nor are they described in literature. 
For a successful immobilisation of ligands containing a keto or an aldehyde group via 
carboxymethoxylamine residues, suitable beads had to be developed. To this aim, an 
appropriate functionalisation of commercially available beads was performed. To 
achieve a carboxymethoxylamine surface functionalisation, N-boc-
carboxymethoxylamine was chosen as derivatisation agent for commercially available 
amino-functionalised beads. 
Testosterone was used as model compound to prove the applicability of this procedure. 
As shown in 4.1.2 (Fig. 15), the derivatisation of amino functionalised matrices using 
N-boc carboxymethoxylamine allows subsequent immobilisation of testosterone. Since 
keto groups are seldom present in natural compounds or drugs, the application of this 
procedure might be limited to a small number of potential ligands. Nevertheless, major 
benefits of this procedure are: (i) the reaction conditions are moderate, thus side reac-
tions or harmful effects to the ligand are improbable; (ii) the derivatisation of the beads 
is easy to be performed with common equipments of a biochemical laboratory; (iii) 
most of the molecules containing a keto group present not more than one keto moiety, 
which allows a specific immobilisation on one defined position without further derivati-
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sation of the molecule. Certainly, this procedure is limited to those molecules where the 
keto group is not essential for the pharmacological activity. 
Establishing this immobilisation strategy offers extended possibilities for ligand immo-
bilisation and target-fishing experiments. 
 
 
5.1.3 Evaluation of fishing conditions 
 
Aside from the chemical composition of the matrix, the fishing conditions play an es-
sential role for a successful target-fishing experiment. 
Since the type of protein fished with a certain ligand is not predictable, an extensive and 
unique development of fishing conditions is not possible. However, several improve-
ments of the fishing conditions could be made in consideration of the general processes 
that are involved in affinity based approaches. 
(i) Only fresh prepared cell lysates were used. Although proteins can be stored for a 
certain time at -80°C, freezing of proteins without appropriate kryoprotecting agents can 
lead to a conformational change of the protein. This could lead to both an alteration of 
3-dimensional structure of the ligand binding side and precipitation of the protein. In 
both cases, the affected protein will not be suitable for a subsequent target-fishing ap-
proach. (ii) 1% of triton® X-100 was used in cell lysis buffers. This enhances the solubi-
lisation of lipophilic proteins. In order to keep solubilised proteins in solution, the same 
concentration of triton® X-100 was used in all following experimental steps. In addition, 
the use of detergent during the fishing-experiment leads to a decreased amount of un-
specifically bound proteins. (iii) Cell lysates were cleared by ultracentrifugation at 
100,000 × g. Thus, a better separation of cell lysate and cell debris is possible. In addi-
tion, ultracentrifugation steps at 4°C allow a separation of lipid components from the 
cell lysate. Since lipids negatively influence subsequent electrophoretical and massspec-
trometric methods, clearing lysates from lipids facilitates subsequent analysis. 
Although individual conditions may be needed for certain experiments, the sum of all 
these improvements led to a reliable procedure that is applicable to a broad range of 
fishing-constructs. 
 
5.1.4 Evaluation of elution condition for target-fishing experiments 
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Needless to say, that fishing a protein is the primary aim of the target-fishing approach. 
Appropriate elution of this protein is as important as the fishing itself. Thus, proteins 
have to be eluted in a purity and amount that allows reliable separation and identifica-
tion later on. 
Standard elution protocols use SDS buffer for protein elution [11]. Since protein denatu-
ration using SDS is needed for subsequent electrophoretic separation by SDS-PAGE, 
SDS buffers combine simple elution and sample preparation for subsequent analysis in 
one step. However, elution by SDS is a rough and highly unselective procedure. How-
ever, other elution agents such as high salt concentrations turned out to be less efficient 
than SDS without improvement of elution selectivity. 
For a more selective elution, proteins were eluted in a competitive manner by addition 
of the ligand itself. For ACAP, ligand concentrations up to 50 mM were used for protein 
elution. Figure 17 shows that a competitive elution results in insufficient protein 
amounts also at these high concentrations. In view of the fact that aqueous buffers are 
needed in proteomic and affinity based approaches, but lipophilic ligands such as ster-
oids or terpenes show poor solubility in aqueous buffers, a competitive strategy of elu-
tion must be considered as an exceptional rather than a general option. 
Since the lack of selectivity was the major disadvantage of common elution procedures, 
we focussed also on the improvement of separation capacities. Using a separation 
method with a high resolution allows the analysis of a large number of proteins. Thus, 
specific bound proteins can be detected in the presence of a high number of unspecific 
bound proteins. 
The gel based method with the highest resolution is the 2-dimensional gel electrophore-
sis (2D-EL). Since urea buffers are needed for the development of the first dimension in 
2D-EL approaches, urea offers the possibility to perform elution and sample preparation 
in one step.  
 
 
5.1.5 Development of a photoreactive linker system 
 
As mentioned above, it is not possible to develop a general method for selective elution, 
independently from the ligand used or the protein fished. Nevertheless, the possibility to 
cleave off the ligand together with the specific bound protein from the matrix would 
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offer an alternative, high selective elution. Thus, we developed a photoreactive linker 
system that could be cleaved by UV light exposure. 
The use of the UV light cleavable linker system allows a highly specific elution of 
ligand bound proteins. UV light exposure of photoreactive beads after a fishing experi-
ment leads to the release of ligand bound proteins. The beads themselves together with 
unspecific bound proteins can be easily removed by centrifugation. Thus, the super-
natant contains only specific bound proteins. 
Although UV reactive molecules and their application in biochemical approaches are 
known [21-23, 141], cleavage of these molecules was not possible without degrading 
proteins. Thus, chemical modifications of the o-nitrobenzylic core as well as modifica-
tions of the irradiation conditions were done in order to develop a protein compatible 
photoreactive linker system. In addition, this linker was designed to be immobilised 
using standard proteinchemistry procedures. Thus, a boc-protected amine on the one 
hand and a carboxy residue on the other allows to connect the matrix, the linker and the 
ligand via amide bonds using the same conditions each time. 
To evaluate the functionality of the UV light cleavable linker, testosterone and its bind-
ing to the androgen receptor (AR) as known interaction was investigated. Figure 21A 
shows that, the beads themselves without ligand added are capable to bind the AR. Fur-
thermore, none of the commonly used methods to prevent this unspecific AR binding, 
such as harsh washing conditions or several surface blocking procedures were success-
ful. In fact, when a specific interaction for a certain protein takes place along with 
strong unspecific binding of the same protein, a selective detection is impossible. The 
UV reactive linker system reduces the amount of unspecific bound protein and facili-
tates the specific release of testosterone bound AR. 
Although the functionality and benefits of UV reactive linker systems could be demon-
strated but exemplary, it was shown that it was possible to establish an effective UV 
light reactive linker system. 
 
5.1.6 Establishment of the 2D-DIGE approach for pull down assays 
 
Two dimensional gel electrophoresis is the protein separation method with a high sepa-
ration performance. Nevertheless, its major disadvantage is its poor reproducibility and 
comparability. By today, the comparison of two different 2D gels is a challenging task. 
The 2D-DIGE allows to analyse up to three protein samples on the same gel. Thus, the 
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samples are easily comparable since all samples run under exactly the same conditions. 
Originally the DIGE technology was developed to compare protein expression patterns 
within differentially treated cells. This application differs from the target-fishing ap-
proach for the buffers used and the amount of proteins obtained. For this reason, novel 
DIGE conditions had to be evaluated. The conditions we developed resulted in a suffi-
cient CyDye labelling of eluted protein. With BSA as model protein, amounts as low as 
5 pg could be detected. Therefore, the optimised DIGE approach offers both high reso-
lution and high sensitivity for the analysis of target-fishing eluates. 
Unfortunately, the high sensitivity of the DIGE approach could not be reached with 
other methods that are required for a reliable target identification and validation. Thus, 
although a large number of proteins can be quantitatively analysed in DIGE experi-
ments, the subsequent analytical steps are limited to a smaller number of highly abun-
dant target candidates. Considering the remarkable progress in proteomic methodolo-
gies, today´s sensitivity of 2D-DIGE analytics will be needed for combination with pro-
teomic methods of tomorrow. 
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5.1.7 Target-fishing experiments with specific bioactive agents 
 
5.1.7.1 Acetaminophen (ACAP) 
 
ACAP is used for a long time [37-38] as a antipyretic and analgesic drug [38, 40]. Until 
today, there is a big discrepancy between the wide spread use of ACAP and the knowl-
edge about its pharmacologic action. Although several targets have been discussed [41-
47, 51-53] for ACAP, none of these targets could explain the entire pharmacological 
profile of it. Thus, target-fishing experiments were performed in order to identify new 
target candidates for ACAP. 
For the target-fishing approach using ACAP as ligand, three different immobilisation 
strategies were applied and fishing experiments were performed in different cell lysates 
by testing different fishing and elution conditions. Nevertheless, no protein could be 
identified as potentially new target candidate. 
Regarding the therapeutic application, where ACAP is used in doses up to 1000 mg per 
single dose, it is conceivable that a high dose of an active compound implicates a low 
affinity to the target. Knowing that molecular interactions like hydrogen bonds, ionic- 
or hydrophobic interactions are needed for a binding of a drug to a corresponding target 
allows to predict the binding mode of a molecule. Typically, molecules with more func-
tional groups allow more interactions with a target which results in a higher binding 
affinity. In addition, size and flexibility of molecules affect their possibility to coordi-
nate functional groups in sterical proximity to interacting groups. Thus, inflexible and 
large molecules typically show a higher binding selectivity. ACAP possesses only few 
functional groups and is relatively small. Therefore, the interaction of ACAP and a pos-
sible target is expected to have neither a high affinity nor a high selectivity.  
The fact that it was not possible to identify new targets for ACAP with the target-fishing 
approach is caused rather by the chemical nature of ACAP than by methodological defi-
ciencies. 
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5.1.7.2 Indirubin-3-monoxime 
 
Indirubine-3´-monoxime (IR3MO), is one active ingredient of Indigo naturalis. Extracts 
of Indigo naturalis were traditionally used in chinese medcine for the treatment of 
leukaemic diseases. Although the antileukaemic action of IR3MO seems to bee partially 
understood [78-79], IR3MO possesses also anti-inflammatory properties that are not 
understood in detail to this day [82-83]. To expand the knowledge of both: 
antileukaemic- and anti-inflammatory actions of IR3MO, target-fishing experiments 
were performed using immobilised IR3MO. 
After successful immobilisation of IR3MO, the respective fishing experiments were 
performed with VSMC, PBMC and PMNL cell lysates. The DIGE analysis of the fish-
ing eluates showed low protein concentrations in general. Thus, although specific fished 
proteins could be detected in the DIGE experiments subsequent visualisation by silver 
staining and identification by MS were not possible. Due to the fact that low protein 
amounts were observed in all IR3MO fishing experiments independent of the type and 
the concentration of the cell lysate, it may be reasonable that the fishing construct itself 
is responsible for the low amount of fished protein. Regarding the poor chemical reac-
tivity of the monoxime residue, a moderate immobilisation rate could be the reason for 
low amounts of bound protein. Thus, a derivatised IR3MO with a more reactive binding 
side for a higher immobilisation rate would be needed. 
 
 
5.1.7.3 Myrtucommulone (MC) 
 
MC is an active ingredient of the mediterranian plant Myrtus communis. Although re-
markable progress on the understanding of the pharmacological actions of MC has been 
made during the last decade [85-87, 151-152] direct binding partners of MC are still 
unknown. 
DIGE analysis of MC fishing experiments showed exactly the same pattern for the MC 
fishing construct and its control. Thus, no differences or specific fished proteins could 
be detected. A possible reason for this result might be an insufficient immobilisation of 
MC. The fact that the -OH residues of MC are either vinylogue acids or phenolic -OH 
residues which show poor reactivity in comparison with primary -OH residues could 
explain an inadequate outcome of MC immobilisation. In addition the reactive groups of 
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MC are sterically hindered. Thus, there might be too little space for an immobilisation 
reaction. 
To avoid problems regarding poor reactivity and sterical influences MC derivatives con-
taining a linker molecule will be synthesised by our cooperationIX partners to allow a 
sufficient immobilisation. 
 
 
5.1.8 Betulinic acid (BA) 
 
BA is a pentacyclic triterpene derived from the white birch tree (Betula alba). While its 
antiviral activity is well understood [91, 93, 95] the background of its anti-inflammatory 
and antitumorous effects remain unclear [88-90, 94]. To identify putative BA targets 
that are responsible for anti-inflammatory and antitumorous effects, fishing experiments 
using immobilised BA were performed. 
The BA fishing was performed in a semiquantitative way where different amounts of 
ligand were immobilised to the matrix. Thus, protein bands on a silver stained SDS-
PAGE that showed enhanced intensity by increasing the amounts of immobilised BA 
are meant to be provoked by specific binding events. In contrast, bands that show simi-
lar intensities for different amounts of immobilised ligand are considered to be unspe-
cific. This strategy of analysis allows the identification of specific, ligand-bound pro-
teins, even if they bind additionally in an unspecific way to the matrix. 
For the BA fishing experiments in PMNL cell lysate, one band with an intensity pattern 
that correlates to the amount of immobilised BA could be identified. Lupeol was used as 
control compound because of its similarity with BA. In this way, on one hand less po-
tential targets can be identified, on the other hand this smaller number of target candi-
dates might be more specifically bound.  
Massspectrometric identification showed that this band consists of two proteins, pro-
teinase 3 (PR3) and cathepsin G (CG). These results could be confirmed by Western 
blot experiments. Testing BA in a CG activity assay showed that the activity of CG is 
not affected at all. In contrast, the activity of PR3 is affected specifically by BA and not 
by lupeol. Thus, BA can be seen as specific inhibitor for PR3 with an IC50 value of 
about 30 µM. 
                                                 
IXProf. Dr. J. Jauch, Universität des Saarlandes, Organische Chemie II, Saarbrücken, Germany 
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PR3 like CG and the human leukocyte elastase (HLE) is one of three serine proteases 
released from neutrophil blood cells [153]. PR3 is a cationic serine protease basically 
contained in azurophil granules of human polymorphonuclear cells. Indeed, PR3 is also 
present in other granules of PMN [154] as well as in monocytes, basophils and mast 
cells [155]. PR3 plays a key role in the pathogenesis of Wegener´s granulomastitis, an 
inflammatory disease leading to respiratory burst and PMN degranulation and thereby 
to vascular inflammation and injury [156-157]. Furthermore, PR3 is known to activate 
precursor forms of cytokines such as TNFα, IL-8 and IL-1β, thus being involved in the 
regulation of inflammatory response [158-159]. Therefore, anti-inflammatory effects of 
BA could at least be partially explained by the inhibition of PR3. 
 
 
5.1.9 Resveratrol 
 
Since Resveratrol (RV) was described as the compound, that is responsible for benefi-
cial effects of red wine [55], RV became a popular compound for medicinal- and phar-
macological investigations. Up today, a vast variety of effects of RV were observed in 
clinical trials and bioassays [58-72, 74-76]. However, most effects of RV can not be 
explained on the molecular level. 
RV fishing experiments and subsequent DIGE analysis led to the identification of a 
group of spots that were selectively fished with RV. Evaluation of single spots showed a 
volume ratio up to 1459% showing a very high selectivity for RV. The spots of the 
identified groups differed in their isoelectric point but not in their size, suggesting that 
one group consists of one protein in different posttranslational modification forms. 
Thus, one spot of each of the three identified groups was analysed by MS. All analysed 
spots were clearly identified as KH-domain splicing regulatory protein (KHSRP). Sub-
sequent Western blot analysis confirmed the MS results and the selectivity of this inter-
action for RV. 
KHSRP also known as far upstream binding protein (FUBP or FBP) belongs to the fam-
ily of the turnover and translation regulatory mRNA-binding proteins (TTR-RBPs) 
[160]. Proteins of this family prominently influence oxidant-triggered gene expression. 
Although detailed mechanisms of TTR-RBPs are not completely understood, they are 
known to influence mRNA stability and translation [161-162]. KHSRP is known to 
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cause posttranslational decay of c-fos, c-jun, iNOS, TNF-α and IL-2 mRNA [160, 162-
164]. 
KHSRP is directly phosphorylated by the upstream kinases PI3K and p38 MAPK [161]. 
Phosporylation by PI3K at Ser 193 promotes the association of KHSRP with 14-3-3 
proteins. After association with 14-3-3, KHSRP looses its ability to enter the exosome 
and thereby its mRNA decay-promoting function. Phosphorylation of KHSRP by p38 
MAPK abrogates the binding of KHSRP to its target mRNA [163, 165]. In addition to 
these effects, KHSRP is known to be a transcriptional activator of c-myc proto-
oncogene.  
Interestingly KHSRP causes posttranslational decay of iNOS, TNFα and interleukins 
and RV affects the expression or production of iNOS, TNFα [166-168] and IL-6. Thus, 
these known effects of RV could be explained by a functional influence of RV with 
KHSRP. However, the exact mode of interaction between RV and KHSRP requires 
more detailed evaluation. 
 
 
5.1.10 Testosterone and progesterone  
 
The classical role of testosterone and progesterone as gender specific steroid hormones 
is known and understood for a long time [132-133]. Besides this knowledge, only few 
attention was given to additional effects of these hormones especially regarding their 
influence on the incidence and progression of inflammatory disease. While healthcare 
professionals recognised in the last decade, that there are diseases that are closely re-
lated to steroid hormone levels [97-99, 101-104, 106, 108], more detailed investigations 
on the molecular level are matter of current pharmacological research [96]. In 2008 Per-
gola et. al. found out that leukotriene biosynthesis depends on androgen levels [96]. So 
further investigations via the target-fishing approach would certainly make sense. 
To perform fishing-experiments using testosterone and progesterone as bait, four differ-
ent immobilisation strategies were tested (see Fig. 43). Since testosterone modifications 
of C17 led to a loss of biological function in terms of ERK activation, C3 modified ster-
oids have been used for the subsequent experiments. 
 
First fishing experiments using 1D electrophoretic separation methods led to the discov-
ery of HSA and karyopherin β (KPN-β) as binding partners of testosterone. Since the 
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testosterone/albumin interaction is known for a long time [143], this result shows that 
testosterone immobilised via the C3 position retains structural features required for in-
teraction with (at least certain) known targets and is at least suitable to confirm known 
interactions. 
Karyopherins are a class of proteins that regulate the import and export of macromole-
cules through the nuclear membrane. According to the direction of transport they are 
divided into importins and exportins [169-170]. For an importin mediated transport into 
the nucleus, proteins need a nuclear localisation signal sequence which is recognised by 
importin α. Thereafter KPN-β (also named importin β) binds to the imporin α-protein 
complex and shuttles it through the nuclear envelope. Inside the nucleus, binding of the 
small GTPase Ran causes the dissociation of the complex and thus, the nuclear release 
of the imported protein [171-175]. Furthermore KPN-β plays an essential role in nuclear 
assembly after mitosis [176-177]. Therefore, the interaction between KPN-β and testos-
terone could give new insights in the regulation of genomic testosterone effects that 
depend on a nuclear import of testosterone bound androgen receptors. Regarding the 
role of KPN-β in nuclear assembling after mitosis could be a starting point for an expla-
nation of cellular regulation in testosterone dependent tumours. Nevertheless, the high 
affinity of KPN-β to the matrix itself impeded a further validation and characterisation 
of the testosterone KPN-β interaction. Thus, the relevance of this interaction remains 
unclear. 
 
Comprehensive optimisation processes of the target-fishing approach led to enlarged 
possibilities in the identification of new target candidates. Above all, the 2D-DIGE ap-
proach allowed a high sensitive analysis of complex samples. Pursuing fishing experi-
ments using the DIGE technique were performed in all three major blood cell types that 
are: PMNL, PBMC and platelets.  
For fishing experiments performed in PMNL, vimentin (Vim), the leukocyte elastase 
inhibitor serpin B1, heat shock protein beta-1 and nicotinamide phosphorybosyltrans-
ferase (NAMPT) were identified as potential target candidates. In PBMC cell lysates, 
the heat shock protein beta- could be identified as potential targets and fishing experi-
ments in platelet lysates again led to the identification of Heat shock protein 27. Subse-
quent Western blot analysis showed, that Vim is selectively bound to progesterone and 
not to testosterone in PBMC lysates, whereas fishing results in PMNL cell lysates did 
not show selectivity for one of both steroids. 
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The protein Vim as intermediate filament is part of the cytoskeleton. Unlike other com-
ponents of the cytoskeleton, Vim seems not to be essential for cell viability. The col-
lapsing of Vim networks does not induce cell shape changes [178], nor does it affect 
mitosis [179], cell growth or proliferation [145, 180-181]. Vim -/- mice show normal 
growth, cell morphology and physiological properties [182-183]. These findings suggest 
that the function of Vim is not limited to the classical cytoskeletal functions. In fact, 
Vim spans from the nucleus to the cell membrane [184] and is known to transmit me-
chanical signals into biological responses [148, 185]. Furthermore, Vim was shown to 
be essential for intracellular protein translocation [146] and Vim deficient cells showed 
decreased motility and chemotactic migration [186]. These findings implicate that Vim 
plays an important role in subcellular organisation. 
It was also found that Vim upregulation is related to the metastatic potential of prostate 
cancer [187] and serum Vim is discussed as a surrogate marker for tumours [188]. In 
addition, Vim is involved in lymphocyte adhesion and transmigration [189]. The fact 
that Vim binds ERK and preserves its activation state while binding it [146] as well as 
the finding that Vim plays an important role in agonist stimulated ERK activation via 
β3-adrenergic receptors [144, 147] gives a connection between Vim and inflammatory 
diseases. First concrete examples for the involvement of Vim in rheumatic diseases 
have already been shown [190]. Nevertheless, detailed mechanisms of the observed 
Vim effects are unclear and methods to analyse and characterise the functionality of 
Vim are not known by today. Thus, an evaluation of functional effects of a testosterone-
Vim interaction is not possible. 
 
Serine protease inhibitors (serpins) are the largest and most widely distributed super 
family of endogenous protease inhibitors. Serpins are involved in regulating physiologi-
cal processes such as blood coagulation, complement activation, tumor suppression and 
inflammation [191-192]. Serpin B1 was initially found in high levels in monocytes and 
neutrophils as a fast acting elastase inhibitor and is therefore also known as mono-
cyte/neutrophil elastase inhibitor (MNEI) [193]. It is one of the most efficient inhibitors 
of the neutrophil proteases HLE, CG and PR3 [194-195], thus implicating an important 
role in inflammatory diseases. In fact, serpin -/- mice are characterised by excessive 
inflammation and deficient immunological response to bacterial infections [196]. The 
stimulation of serpin activity or serpin release offers the possibility of anti-inflammatory 
pharmacological intervention that is yet not considered by today. However, Western 
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blot analysis of testosterone and progesterone fishing eluates showed that serpin B1 
binds to both steroids. Thus, although testosterone and progesterone might have an in-
fluence on the Serpin B1 activity, this may not explain gender specific effects or selec-
tive sex hormone effects. 
 
Visfatin was originally identified as the protein pre-B-cell colony enhancing factor 
(PBEF) [197]. In 2005 Fukuhara et al. discovered the adipokine function of PBEF in 
visceral fat and named it visceral fat adipokine or in brief visfatin (Vis) [198]. They 
could also show that Vis is mimicking insulin effects. Although it was originally found 
in visceral fat tissue, Vis is known today as an ubiquitiniously expressed protein [197, 
199]. In addition, Vis was previously known as nicotinamide phosphoribosyl transferase 
(NAMPT) due to its enzymatic activity in the NAD synthesis [200]. The characterisa-
tion of this versatile protein can therefore be divided in three parts according to its func-
tion. (i) Transferase activity; whether the transferase activity of Vis directly correlates 
with its cytokine-like function is still not clear [201-202]. Nevertheless, it was shown 
that the inhibition of the transferase activity via FK866 at least, leads to a reduction of 
cytokine production in inflamatory cells [203]. Inhibition of Vis also caused depletion 
of intracellular NAD levels resulting in apoptotic cell death [203]. (ii) Insulin mimicking 
effects; it was shown that Vis directly binds to the insulin receptor [198]. Additionally 
the Vis plasma levels are elevated in type-II diabetes patients [204]. Experiments using 
Vis +/- mice showed that there is an impaired glucose tolerance in these mice. Taken 
together, there is an interesting correlation between Vis and glucose metabolism related 
diseases. The exact role of Vis is however poorly understood. The combination of insu-
lin modulating effects of adipokines and their higher levels in obese people are sug-
gested to explain at least a part of the pathogenesis of the metabolic syndrome. (iii) Adi-
pokine effects; adipokines are cytokines classically released from adipocytes and are 
closely related to inflammatory diseases [201, 205]. Chen et al. showed that there is an 
increase of inflammatory markers at high Vis plasma levels [204]. Especially the patho-
genesis of endothelian dysfunction and rheumatoid arthritis is known to be affected by 
Vis [206-210]. On the cellular level it was shown that Vis induces production and secre-
tion of cytokines such as IL-1β, IL-6 and TNFα [211]. In addition, Vis causes AKT and 
ERK phosphorylation as well as PI3K upregulation [149] and thereby activation of 
eNOS [150]. An increase of NFκB activation by Vis could also be shown [212]. 
 5 Discussion  121 
Regarding the gender specific prevalence for inflammatory diseases, Vis could be of 
interest concerning its role in inflammatory diseases and gender specific regulation. 
Although some authors excluded gender specific expression of Vis [213], other studies 
stated that there are gender differences. It was shown that there are higher levels of 
plasma Vis in girls [214] and that Vis levels elevated during pregnancy [215-216]. In 
addition, it was shown that testosterone in a nanomolar range decreases Vis expression 
[217]. 
Western blot analysis of testosterone and progesterone fishing eluates showed a selec-
tive binding of Vis to testosterone. Fishing experiments using isolated recombinant Vis 
indicated that Vis binds directly to testosterone but not to progesterone. Since Vis, like 
testosterone, increases the phosphorylation state of ERK [96, 149], synergistic effects of 
both compounds were evaluated. In fact, the addition of both testosterone and Vis led to 
a slightly higher phosphorylation state of ERK than one of these compounds alone. Be-
cause female plasma contains lower testosterone levels and higher Vis levels compared 
to male plasma, it may be reasonable that testosterone amplifies the Vis mediated ERK 
activation to achieve a similar basal ERK phosphorylation level in male. However, ad-
ditional knowledge is needed to clearly understand the functionality of the testoster-
one/Vis interaction. 
 
The heatshock protein 27 (HSP27) also known as heat shock protein B1 was first dis-
covered in 1962 [218] and belongs to the family of small HSPs. It is ubiquitously and 
abundantly expressed [219] and plays a major role in cellular stress response. Further-
more, it is responsible for protein refolding [220] due to its chaperon activity [221-223]. 
The regulation of HSP27 is poorly understood. It is known that HSP27 dimers form 
oligomeres up to 1000 kDa [224-225] and phosphorylation causes detachment of dimers 
leading to decreased size of oligomers [226]. However, it is not clear whether large or 
small oligomers in phosphorylated or unphosphorylated state are the active form [224, 
227-228]. 
HSP27 can be phosphorylated at Ser 15, 78 and 82 by AKT [229] or MK2 [230-231] 
via a p38 dependent [232-234] or independent [235-236] pathway. It regulates the integ-
rity of microfilaments [237-238] and intermediate filaments [239] and binds directly to 
vimentin [240]. 
It was shown that HSP27 has cytoprotective properties during cellular stress [241] such 
as heat shock, cytokine release and growth factor release [223, 234, 236, 241-242]. In 
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addition it was shown that its expression is induced by heat shock, gamma radiation, 
UV light exposure, infections [243-245] and oxidative stress [246-247]. 
There is also a close link between HSP27 and inflammation [248-250]. It was shown, 
that HSP27 regulates the NFκB dependent production of inflammatory mediators 
TNFα, PGE2 IL-8, IL-1α [251] and increases NFκB activity via increase of IκB-α deg-
radation [252]. RNAi downregulation of HSP27 leads to an increase of IL-1 induced 
COX-2, IL-6 and IL-8 levels [249]. It was therefore suggested to be involved in the 
pathogenesis of atherosclerosis [253] in a gender-dependent manner [254-255]. More-
over HSP27 as potent antiapoptotic factor [246, 256] plays an important role in cancer. 
High levels of HSP27 in various tumors such as breast [257], gastric [258], ovarian 
[259], endometrial [260], glial [261], and prostate cancer [262] are correlated with poor 
prognosis, resistance [257, 263-268] and decreased chemosensitivity [265, 269-270]. As 
a result of these findings OGX-427 as a HSP27 antisense drug was developed and is 
currently tested in a phase I study. The role of HSP27 in cancer is closely related to 
steroid hormone pathways. Thus, the HSP27 gene is one of the most highly expressed 
genes in androgen independent prostate tumors [271] and is required for translocation 
[272], transcriptional action [273] and palmitoylation of PR and AR [272]. In turn, an-
drogen bound AR induces rapid HSP27 phosphorylation [233]. Given that the PR [274-
275] and AR [127, 276] mediate ERK signalling, connects HSP27 with gender specific 
regulation of inflammatory diseases. 
Interestingly, HSP27 was fished in platelets with both, testosterone and progesterone. 
HSP27 was identified for two different, clearly separated spots once selectively with 
testosterone and one with progesterone. These two spots differed not in their size but 
rather in their isoelectric points. Given, that no isoforms of HSP27 are known so far, a 
closer look was taken on the phosphorylation state of HSP27 which may cause a shift in 
the IEP. Western blot analysis of fishing eluates obtained from fishing experiments us-
ing PBMC and PMNL cell lysate as protein source showed that HSP27 could be fished 
with both steroids with only a slightly higher affinity for testosterone. In contrast, the 
same experiments using platelet lysate as protein source showed a high selectivity for 
testosterone and it was not possible to pull down HSP27 with progesterone in platelets. 
Analysing the platelet-derived fishing eluates using a phosphor-specific p(Ser82)HSP27 
antibody showed that it is possible to pull down pHSP27 with progesterone. Consider-
ing that the common HSP27 antibody recognises both, HSP27 and pHSP27 but the 
p(Ser82)HSP27 antibody only the phosphorylated form implies that the affinity of 
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pHSP27 to progesterone is higher than to testosterone, though there is also a prominent 
band for pHSP27 in the Western blot experiment for the testosterone sample. As men-
tioned above, it is unknown whether the phosphorylated or the unphosphorylated form 
of HSP27 can be seen as active form. Thus, it is difficult to speculate about the physio-
logical relevance of phosphorylation dependent affinity of HSP27 to the sex hormones. 
Nevertheless, using isolated HSP27 for fishing experiments showed that the HSP27 
testosterone interaction is a direct interaction. Taking into account that isolated HSP27 
is completely unphosphorylated, no signal could be obtained for progesterone in this 
experiment. To get a closer insight in the physiological relevance of these interactions, 
HSP27 and pHSP27 levels in platelets from male and female donors were measured. 
Whereas the ratio between phosphorylated and unphosphorylated HSP27 were similar 
in platelets from both genders, platelets from female donors turned out to have distinct 
higher levels of both, HSP27 and pHSP27. Assuming that the interaction between 
HSP27 and testosterone or progesterone affects physiological procedures it seems to be 
reasonable that there is a stronger interaction between HSP27 and testosterone to com-
pensate the lower HSP27 levels in male platelets. 
 
To investigate whether steroids immobilised via the C3- or over the C7 position are 
more suitable for fishing experiments a multiplexed DIGE approach was performed. 
This way, a statistical evaluation of two 2D gels compared over a pooled internal stan-
dard gave insights into the distribution and selectivity of fished proteins. Using the same 
batch of cell lysate in same amounts for both experiments leads to reliable and compa-
rable results. After exclusion of artificial spots, fishing experiments using C3-
immobilised steroids lead to a discovery of 1472 spots whereas C7- derivatives were 
able to pull down 3937 proteins. In addition, the C7 derivatives showed with 72.0% a 
lower quota of unspecific bound protein than C3 derivatives with 80.7%. Thus, the 
combination of both, more fished proteins and more selective fished proteins indicates 
that the C7 derivatives are more suitable for fishing experiments. Taken together, 282 
proteins could be selectively fished with one of the C3 derivatised steroids whereas C7 
derivatised steroids were able to fish 1104 proteins selectively in the same cell lysate. 
 
In the course of this study, so far unknown binding partners of testosterone and proges-
terone could be identified. Furthermore, it could be demonstrated, that the influence of 
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HSP27 and Vis on inflammation are affected by testosterone and progesterone respec-
tively. 
The finding, that testosterone amplifies the visfatin mediated ERK phosphorylation 
could at least partially explain and affirm the findings of Pergola et. al. [96]. Although, 
these results can not explain all observed effects regarding gender specific regulation of 
inflammatory processes, they can be seen as starting point for further investigations 
such as whole blood assays or in vivo experiments to determine the physiological rele-
vance of these findings. The intention of these investigations is the comprehension of 
gender specific inflammatory effects that allows a rational, gender specific pharmaco-
therapy of inflammatory diseases. 
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Pull-down assays are suitable and valuable tools to evaluate drug-target interactions as 
well as a vast variety of other ligand protein interactions. In so-called target-fishing ex-
periments a drug, covalently bound to an insoluble matrix, is incubated with a cell lys-
ate as source of target proteins. Thus, drug bound proteins can be isolated and identified 
by appropriate protein analytics. 
This work describes essential methodical improvements as well as the exemplary appli-
cation of this method to identify targets for selected active compounds with so far un-
characterised anti-inflammatory properties. 
 
The methodological part of this work we could achieve: (i) essential improvements of 
conditions for the target-fishing approach, (ii) innovative strategies for ligand immobili-
sation, (iii) the development of a biocompatible UV light cleavable linker system, (iv) 
the development of a semiquantitative fishing approach for determination of selective 
and unselective bound proteins as well as (v) the development of 2D-difference gelelec-
trophoresis for analysis of target-fishing eluates. 
To improve general fishing conditions the influence of selected buffer systems, elution 
conditions, matrix modifying procedures and the preparation of cell lysates as source of 
target proteins was extensively evaluated. For the generation of novel fishing constructs, 
new immobilisation strategies had to be found. Thus, the immobilisation of compounds 
over non-reactive monoxime residues could be achieved. Furthermore, a novel method 
for immobilisation of ligands over keto- and aldehyde residues could successfully be 
developed. For this purpose a procedure for the production of carboxymethoxylamine 
activated matrices was established. 
Since incubation of matrix-coupled ligands with proteins leads to both: specific protein-
ligand interactions as well as unspecific protein-matrix interactions, we developed tech-
niques that either allow the differentiation between selective and unselective bound pro-
teins or essentially bypasses problems related to unspecific protein-matrix interactions. 
Thus, a semi-quantitative target-fishing approach as well as novel linker strategies were 
established. 
We designed a biocompatible, daylight stable UV light reactive linker system which 
allows us to cleave off immobilised ligands together with the bound protein(s) simply 
by UV light exposure. This linker system is based on an o-nitrobenzylic core that can be 
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cleaved via norrish type II reaction. Using the known testosterone-androgen receptor 
interaction we could show that the use of this cleavable linker system results particu-
larly in the elution of specific bound proteins. 
To advance the analytics of fished proteins, the 2D-DIGE approach was established and 
modified to the requirements of the target-fishing approach. 
 
In the course of this study the serine proteases proteinase 3 (PR3) and Cathepsin G (CG) 
were identified as binding partner of betulinic acid (BA). BA was shown to inhibit the 
enzymatic activity of PR3 with an IC50 value of 30 µM, whereas the activity of GC was 
not affected at all. Thus, BA can be seen as a selective PR3 inhibitor. 
The use of a resveratrol (RV) derivative for target-fishing experiments resulted in the 
identification of the KH-domain splicing regulatory protein (KHSRP) as binding part-
ner. The interaction of RV with KHSRP could be the starting point for the explanation 
of known in vivo effects of RV. 
The steroid hormones testosterone and progesterone were used for target-fishing ex-
periments in order to investigate non-genomic effects and the molecular reason for their 
influence in inflammatory diseases. The proteins Vimentin, Serin protease B1, Visfatin 
(Vis) and Heatshock protein 27 (HSP27) were identified as binding partners of steroid 
hormones. In more detailed experiments Vis was found to bind directly and selectively 
to testosterone. Furthermore, it could be shown, that testosterone amplifies the ERK 
activating properties of Vis, which gives new insights in the gender specific regulation 
of basal ERK phosphorylation levels. 
HSP27 was identified as binding partner for both: testosterone and progesterone. It 
could be shown, that the binding affinity of both steroids to HSP27 depends on the 
phosphorylation state of HSP27. These findings could explain a stronger interaction 
between HSP27 and testosterone to compensate the lower HSP27 levels in male plate-
lets. 
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7 Zusammenfassung 
 
Der Pull-down Assay ist ein nützliches Werkzeug für die Identifizierung und 
Evaluierung von Arzneistoff Zielstrukturen. In sogenannten “Target-Fishing” Experi-
menten wird ein Arzneistoff oder eine pharmakologisch aktive Substanz kovalent an 
eine unlösliche Matrix gebunden und mit einen Zelllysat als Proteinquelle inkubiert. 
Proteine, die hierbei an den Arzneistoff binden, können isoliert und identifiziert werden. 
Diese Arbeit beschreibt grundlegende Verbesserungen sowie die beispielhafte An-
wendung zur Identifizierung von Zielstrukturen für bislang uncharakterisierte, anti-
entzündliche Wirkungen ausgewählter Substanzen. 
Im methodischen Teil dieser Arbeit werden (i) grundlegende Verbesserungen experi-
menteller Bedingungen, (ii) innovative Strategien der Liganden Immobilisation, (iii) die 
Entwicklung eines biokompatiblen, UV Licht spaltbaren Linker-Systems, (iv) die Etab-
lierung einer semi-quantitativen Fishing-Methode zur Unterscheidung zwischen selektiv 
und unselektiv gebundenen Targets sowie (v) die Etablierung der zweidimensionalen-
differential Gelelektrophorese für die Analyse von Target-Fishing Eluaten, dargestellt. 
 
Für die Verbesserung grundlegender, experimenteller Bedingungen des Target-Fishings 
wurde der Einfluss verschiedener Puffer-Systeme, Matrixmodifikationen und Methoden 
zur Herstellung von Zelllysaten untersucht. Es wurden neuartige Strategien zur Immobi-
lisierung pharmakologisch aktiver Substanzen entwickelt. So konnten Liganden über 
Monoxim-Funktionen an Epoxy-aktivierte Matrices gebunden werden. Des Weiteren 
wurde ein Verfahren zur Herstellung Carboxymethoxylamin aktivierter Oberflächen für 
die Immobilisierung von Liganden über carbonyl Funktionen entwickelt. 
Da die Inkubation von Matrix gebundenen Liganden sowohl zu spezifischen als auch zu 
unspezifischen Protein-Liganden Interaktionen führt, wurden Methoden entwickelt, um 
zwischen spezifischen und unspezifischen Interaktionen zu unterscheiden oder Prob-
leme hinsichtlich unspezifisch gebundene Proteine generell zu umgehen. So wurden 
eine semi-quantitative fishing Methode und neuartige Verknüpfungsstrategien etabliert. 
Wir konnten ein biokompatibles, Tageslicht stabiles UV Licht spaltbares Linker-System 
entwickeln, das eine Abspaltung des Liganden-gebundenen Targets durch Bestrahlung 
mit UV Licht ermöglicht. Die Funktionalität dieses Linker-Systems wurde anhand der 
bekannten Testosteron- Androgenrezeptor Interaktion unter Beweis gestellt. Um 
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zusätzlich die Analytik gefischter Proteine zu optimieren, wurde die 2D-DIGE Methode 
etabliert und an die Anforderungen des Target-Fishings angepasst. 
Im Rahmen dieser Arbeit wurden die Serinproteasen Proteinase 3 (PR3) und Cathep-
sin G (CG) als Bindungspartner für Betulinsäure identifiziert. Es konnte gezeigt werden, 
dass Betulinsäure die Aktivität der PR3 mit einem IC50 Wert von 30 µM inhibieren 
konnte, während die Aktivität von CG nicht beeinflusst wurde. Damit kann BA als se-
lektiver Inhibitor der PR3 gesehen werden. 
Mit der Verwendung von Resveratrol (RV) als Ligand für target-fishing Experimente 
konnte das KH-domain splicing regulatory protein (KHSRP) als Bindungspartner für 
RV identifiziert werden. Dies bietet einen neuartiger Ansatzpunkt für die Erklärung 
bekannter in vivo Effekte des Resveratrols. 
Des weiteren wurden die Steroidhormone Testosteron und Progesteron für target-fishing 
Experimente verwendet, um die physiologischen, nichtgenomischen und anti-
inflammatorischen Effekte dieser Substanzen zu untersuchen. Hierbei konnten die Pro-
teine Vimentin, Serin Protease Inhibitor B1, Visfatin (Vis) und Heatshock protein 27 
(HSP27) als Bindungspartner dieser Steroidhormone identifiziert werden. In weiteren 
Experimenten konnte gezeigt werden, dass Vis direkt und selekiv an Testosteron bindet. 
Wir konnten des Weiteren zeigen, dass Testosteron die ERK aktivierenden Eigen-
schaften des Vis verstärkt und damit neue Erkenntnisse über die geschlechtsspezifische, 
basale Regulation der ERK-Phosphorylierung erbracht hat. 
HSP27 wurde sowohl als Bindungspartner für Testosteron als auch für Progesteron 
identifiziert. Es konnte gezeigt werden, dass die Bindungsaffinität beider Steroide vom 
Phosphorylierungsstatus des HSP27 abhängt und Testosteron eine höhere Affinität zu 
unphosphoryliertem HSP27 hat, während Progesteron bevorzugt an die phosphorylierte 
Form bindet. 
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